Digchip : Database on electronics components
Electronics components database



Companies news of 2010-05-21 (page 5)

  • HSN and Harrah's Entertainment Join Together for Star-Studded Multi-Million Dollar...
  • Mezzo Technologies and Andretti AutoSport Win 2010 BorgWarner Louis Schwitzer AwardMezzo...
  • Valley National Bancorp Sets Record and Payment Date for Common Stock Cash Dividend
  • Tefron Reports First Quarter 2010 Results
  • Green Earth Technologies Has a New Ultimate Biodegradable Solution for the Gulf Oil Spill...
  • Borders Raises $25 Million Through Equity Financing to Support Key Financial and Strategic...
  • AerCap Signs Debt Facilities for Total of US$190 Million With Three Banks From Europe and...
  • DuPont Titanium Technologies Announces a Price Increase for Ti-Pure(R) Titanium Dioxide...
  • Oncothyreon announces presentations at American Society Of Clinical Oncology (ASCO) Annual...
  • DuPont Titanium Technologies Announces a Price Increase for Ti-Pure® Titanium Dioxide...
  • PLC Medical Systems to Demonstrate RenalGuard® at EuroPCR 2010Company to Hold First...
  • Blur(TM) Features Innovative In-Game Facebook(R) IntegrationBizarre Creations' Powered-up...
  • Annual Welcome Back Awards Program Honors Individuals for Tremendous Contributions to the...
  • China TransInfo to Hold Annual Meeting of Stockholders in Beijing
  • AIVtech Retains CCG Investor Relations
  • China BCT Reports First Quarter 2010 Results
  • American Woodmark Corporation Announces Cash Dividend
  • AT&T Unveils New Wireless Store in SalemStore Offers Hands-On, Interactive Retail...
  • Oberthur Technologies and Smart Association Team up to Provide Smart Card-Centric ID...
  • Micromet to Provide Update on BiTE Antibody Development Programs at Upcoming Medical...
  • Ann Taylor Reports Strong First Quarter Earnings Per Share of $0.38-- Results Driven by...
  • YM BioSciences announces presentations on global nimotuzumab trials at ASCO annual meeting...
  • Oncolytics Biotech(R) Inc. Announces Reovirus Research to be Presented at ASCO Annual...
  • Rentrak Announces Top Ten Movies-on-Demand Titles Week Ending May 16, 2010
  • Anadys Announces Completed 12-Week Results From Phase II Combination Study of ANA598 With...
  • Eight Aspiring Professional Gamers Win Big in Chicago at Second Doritos MLG Pro-Gaming...
  • Sembcorp Commences Tender Offer to Acquire All Outstanding Shares of Cascal for US$6.75...
  • DuPont Titanium Technologies annonce une hausse des prix pour les produits en dioxyde de...
  • Naturally Advanced Technologies Raises $1.4 Million
  • AerCap Signs Debt Facilities for Total of $190 Million With Three Banks From Europe and...



    HSN and Harrah's Entertainment Join Together for Star-Studded Multi-Million Dollar Promotion to Celebrate HSN's 33rd Birthday-- Cross-Promotional Marketing Campaign Includes: Online Instant-Win Game & Sweepstakes; Grand Prize Trips to Las Vegas; and Live Television Shopping Event From Planet Hollywood Casino and Resort --

    ST. PETERSBURG, Fla., May 21 /PRNewswire-FirstCall/ -- Shoppers across the country will soon experience all of the fun and excitement of the famous Las Vegas Strip when interactive multichannel retailer HSN and Harrah's Entertainment, Inc. join forces to promote HSN's 33rd birthday with the launch of HSN's "Lucky 33 Birthday Celebration." This multi-million dollar promotion joins together two industry leaders for a highly creative, multichannel marketing campaign that utilizes all of HSN's and Harrah's consumer touch points to reach out to new and existing customers.

    "HSN is constantly striving to deliver new discoveries and a great shopping experience for our customers," states Bill Brand, HSN's Executive Vice President of Programming, Marketing and Business Development. "This exciting new relationship with Harrah's provides HSN with a highly creative and compelling marketing platform from which to launch our birthday celebration. Harrah's has an active member base of 10 million potential customers and we look forward to introducing them to HSN."

    On June 1 the summer-long birthday extravaganza begins with millions of dollars in HSN gift cards becoming available to select Harrah's Total Rewards members through local promotions driving members to 25 Harrah's casino resorts across the country. Additionally, members can visit http://www.totalrewards.com/ to learn how to enter and play the HSN $185K Birthday Giveaway, a fun and interactive online instant-win game and promotion that provides participants the opportunity to win even more HSN gift cards.

    HSN customers can join in the fun at http://www.hsn.com/vegas as HSN celebrates its 33rd birthday with giveaways, savings and special offers for an array of exciting new merchandise that's slated to debut during the month of July. Those who play the game at http://www.hsn.com/ will automatically be entered into a grand prize drawing featured live each night on HSN TV throughout the month of July. Grand prize winners will receive one of 62 trips for two to HSN Live in Vegas, a spectacular, star-studded HSN shopping spree at Harrah's Planet Hollywood Resort and Casino in Las Vegas August 14-15.

    At HSN Live in Vegas, August 14-15, fans will have the opportunity to see some of their favorite personalities, including: celebrity chef Wolfgang Puck; Serious Skin Care founder Jennifer Flavin-Stallone; supermodel, actress and talented jewelry designer Molly Sims; and highly successful inventor and entrepreneur Joy Mangano. All will be broadcasting live on HSN throughout the day on Saturday, August 14. In addition, attendees will be able to utilize HSN gift cards at eight boutique kiosks stocked with HSN merchandise.

    Other personalities scheduled to attend include: Susan Lucci, Tori Spelling, Carol Brodie, Debbie Meyer, Tony Little, Diane Gilman, Randolph Duke, and Rhonda Shear, among others.

    Participating Harrah's Entertainment resorts, include: Harrah's Atlantic City, Bally's Atlantic City, Bally's Las Vegas, Harrah's Cherokee, Caesars Palace, Harrah's Council Bluffs, Flamingo, Grand Biloxi, Harrah's Tunica, Harrah's Atlantic City, Horseshoe Bluffs Run, Harrah's Las Vegas, Imperial Palace, Harrah's Joliet, Harrah's Louisiana Downs, Harrah's Laughlin, Harrah's North Kansas City, Harrah's Metropolis, Planet Hollywood Resort & Casino, Paris Las Vegas, Harrah's Reno, Harrah's Rincon, Showboat Atlantic City, Harrah's St. Louis and the Rio All Suites Hotel & Casino.

    For more information about HSN's Lucky 33 Birthday Celebration, log on to http://www.hsn.com/vegas.

    About HSN

    Headquartered in St. Petersburg, FL, HSN is a leading interactive multichannel retailer offering a curated assortment of exclusive products and top brand names to its customers. HSN incorporates experts, entertainment, inspiration, solutions, tips and ideas to provide an entirely unique shopping experience. At HSN, customers find exceptional selections in Health & Beauty (e.g. M. Asam, Carol's Daughter, Coty, FranBrand, FusionBeauty, Andrew Lessman's Procaps, Lancome, Perlier Beauty, Serious Skin Care, Wei East, ybf Beauty); Jewelry (e.g. Heidi Daus, Grayce by Molly Sims, R.J. Graziano, IMAN Global Chic, michaeLisa, Noir, Amedeo Scognamiglio, Tori Spelling, Signature Statement Serena Williams); Home/Lifestyle (e.g. Nate Berkus, Bissell, Colin Cowie, Dyson, Todd English, GreenPan with Thermolon, Emeril Lagasse, Joy Mangano, MoMA Design Store, Wolfgang Puck); Fashion/Accessories (e.g. American Glamour Badgley Mischka, Curations with Stefani Greenfield, Sam Edelman, Loulou de la Falaise, Chi by Carlos Falchi, Diane Gilman, "Timeless" by Naeem Khan, Adrienne Landau, Twiggy); and Electronics (e.g. Canon, Gateway, GE, HP, JVC, Kodak, LG, Sony).

    A leader in transactional innovation, HSN is the only retailer offering live streaming video on three screens: TV network, which broadcasts live to 94 million households in the US in HD 24/7; hsn.com, which ranks in the top 30 of the top 500 internet retailers and features 15,000 product videos; and mobile via its iPhone application. HSN customers are also able to shop via HSN's live in-flight shopping experience, which launched in late 2009. HSN, founded 32 years ago as the first shopping network, is an operating segment of HSN, Inc. .

    HSN

    CONTACT: Sunny Jenkins of HSN/HL Group, +1-212-529-5533,
    sjenkins@hlgrp.com; or Jacqueline Peterson, Harrah's Entertainment,
    +1-702-494-4829, japeterson@harrahs.com

    Web Site: http://www.hsn.com/




    Mezzo Technologies and Andretti AutoSport Win 2010 BorgWarner Louis Schwitzer AwardMezzo MicroChannel Radiator Reduces Engine Radiator Temperatures up to 8 Degrees Celsius with 'Drop In' Replacement

    AUBURN HILLS, Mich., May 21 /PRNewswire-FirstCall/ -- The 44th annual BorgWarner Louis Schwitzer Award has been awarded to engineers Charles Becnel, Patrick Luke and Christophe Marques from Mezzo Technologies and Tino Belli from Andretti AutoSport for developing the Mezzo MicroChannel Radiator. Designed to fit in the same space and use the same connectors as existing radiators, the Mezzo MicroChannel Radiator significantly reduces coolant temperature with reliable, robust performance. Earlier this year, the IndyCar Series approved the technology for use by all teams.

    Increased cooling capacity results in better engine performance and greater horsepower. Unlike conventional radiators that rely on fin designs to transfer heat, the Mezzo MicroChannel Radiator uses nearly five miles of stainless steel micro tubes measuring less than 0.5 mm (1/50 of an inch) in diameter to reduce engine temperatures up to 8 degrees C (14 degrees F). A corrugated arrangement also increases heat transfer while keeping pressure losses low. Developed by Mezzo Technologies in close cooperation with Andretti AutoSport, the innovation achieved significant results in scale models, wind tunnel testing and in IndyCar. The technology is now being evaluated by other race series as well as the aviation industry.

    Presented to engineers by engineers, the Louis Schwitzer Award rewards individuals with the courage and passion to explore and develop new concepts in racing technology. BorgWarner sponsors this prestigious $10,000 award, which is presented by the Indiana Section of SAE International. The winners' names are added to the Schwitzer trophy on permanent display at the Indianapolis Motor Speedway Hall of Fame Museum.

    The award was initiated in 1967 to recognize a true automotive pioneer. The winner of the first auto race at the Indianapolis Motor Speedway (IMS) in 1909, Louis Schwitzer's fame came not as a professional race car driver, but as an automotive engineer. After working in the automotive industry for many years, Louis founded the Schwitzer Corporation, which produced innovative cooling fans, water pumps and turbochargers. The Schwitzer Corporation joined BorgWarner in 1999. Throughout his career, Louis enjoyed numerous technological accomplishments, supported higher education, led the IMS technical committee for many years and maintained a strong association with SAE.

    Auburn Hills, Michigan-based BorgWarner Inc. is a product leader in highly engineered components and systems for vehicle powertrain applications worldwide. The FORTUNE 500 company operates manufacturing and technical facilities in 61 locations in 19 countries. Customers include VW/Audi, Ford, Toyota, Renault/Nissan, General Motors, Hyundai/Kia, Daimler, Chrysler, Fiat, BMW, Honda, John Deere, PSA, and MAN. The Internet address for BorgWarner is: http://www.borgwarner.com/.

    BorgWarner Inc.

    CONTACT: Erika Nielsen, +1-248-754-0422

    Web Site: http://www.borgwarner.com/




    Valley National Bancorp Sets Record and Payment Date for Common Stock Cash Dividend

    WAYNE, N.J., May 21 /PRNewswire-FirstCall/ -- Valley National Bancorp ("Valley"), the holding company for Valley National Bank, announced today that a common stock cash dividend of $0.18 per share will be paid July 1, 2010 to shareholders of record on June 4, 2010. The $0.18 per share dividend is relatively unchanged as compared to the previous quarterly cash dividend (adjusted for a five percent common stock dividend to be issued May 21, 2010 to shareholders of record on May 7, 2010).

    Gerard H. Lipkin, Chairman, President & CEO of Valley remarked, "Valley's Board continued the dividend relatively unchanged from the prior quarter. Consistent with its conservative philosophy, the Board is committed to examining and weighing relevant facts and considerations each time it makes a decision to pay a cash dividend, including, among other things, current earnings, capital levels, the impact of the current economic recession on Valley's performance, and the Board's commitment to shareholder value. The historical level of dividends paid per share should not be used as an indicator of future levels of dividends to Valley's stockholders."

    About Valley

    Valley is a regional bank holding company, headquartered in Wayne, New Jersey, with over $14 billion in assets. Its principal subsidiary, Valley National Bank, currently operates 202 branches in 135 communities serving 14 counties throughout northern and central New Jersey and Manhattan, Brooklyn and Queens. Valley National Bank is the largest commercial bank headquartered in New Jersey and is committed to providing the most convenient service, the latest in product innovations and an experienced and knowledgeable staff with a high priority on friendly customer service 24 hours a day, 7 days a week. Valley National Bank offers a wide range of deposit products, mortgage loans and cash management services to consumers and businesses including products tailored for the medical, insurance and leasing business. Valley National Bank's comprehensive delivery channels enable customers to bank in person, by telephone or online.

    For more information about Valley National Bank and its products and services, please visit http://www.valleynationalbank.com/ or call Customer Service 24/7 at 1-800-522-4100.

    Forward Looking Statements

    The foregoing contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are not historical facts and include expressions about management's confidence and strategies and management's expectations about new and existing programs and products, relationships, opportunities, taxation, technology and market conditions. These statements may be identified by such forward-looking terminology as "expect," "believe," "view," "opportunity," "allow," "continues," "reflects," "typically," "usually," "anticipate," or similar statements or variations of such terms. Such forward-looking statements involve certain risks and uncertainties. Actual results may differ materially from such forward-looking statements. Factors that may cause actual results to differ materially from those contemplated by such forward-looking statements include, but are not limited to those factors disclosed in our SEC filings, including our Quarterly Report on Form 10-Q for the three months ended March 31, 2010 and Annual Report on Form 10-K for the year ended December 31, 2009.

    Valley National Bancorp

    CONTACT: Dianne M. Grenz, First Senior Vice President, Director of
    Marketing, Shareholder & Public Relations, +1-973-305-4005

    Web Site: http://www.valleynationalbank.com/

    Company News On-Call: http://www.prnewswire.com/comp/141340.html




    Tefron Reports First Quarter 2010 Results

    MISGAV, Israel, May 21, 2010 /PRNewswire-FirstCall/ -- Tefron Ltd. , a leading producer of seamless intimate apparel and engineered-for-performance (EFPTM) active wear, today announced financial results for the first quarter of 2010.

    First Quarter 2010 Results

    Tefron reported revenues for the first quarter of 2010 of $25.8 million. This compares with revenues of $22.3 million in the fourth quarter of 2009 and $47 million in the first quarter of 2009. The Company reported a gross profit in the first quarter of $0.9 million, compared with a gross loss of $2.16 million in the fourth quarter of 2009 and a gross profit of $5.5 million in the first quarter of 2009. Operating loss for the first quarter of 2010 was $3.6 million, compared with an operating loss of $5.6 million for the fourth quarter of 2009 and an operating loss of $0.3 million in the first quarter of 2009. Net loss for the first quarter of 2010 was $3.3 million, equivalent to a loss of $1.5 per diluted share, compared with net loss of $4.7 million in the prior fourth quarter, or a loss of $2.2 per diluted share, and net income of $0.1 million in the first quarter of 2009, equivalent to earnings per diluted share of $0.1.

    Commenting on the results, CEO Amit Meridor, said, "In the first quarter we successfully completed the financial restructuring of Tefron culminating in the agreement with the banks on March 2, 2010 and the rights issue at the end of the quarter on March 25, 2010. The sales and operational results reported today met the targets we presented to the Board of Directors in our budget. We are pleased that having achieved these results, we can now focus on the next stage of the turnaround program with the implementation of stricter quality control, enhanced manufacturing effectiveness and efficiency and more consistent, dependable customer service."

    About Tefron

    Tefron manufactures boutique-quality everyday seamless intimate apparel, active wear and swimwear sold throughout the world by such name-brand marketers as Victoria's Secret, Nike, The Gap, J.C. Penney, Wall-Mart, lululemon Athletica, Calvin Klein, Maidenform, Patagonia, Reebok, , and El Corte Englese, as well as other well known retailers and designer labels. The company's product line includes knitted briefs, bras, tank tops, boxers, leggings, crop, T-shirts, nightwear, bodysuits, swimwear, beach wear and active-wear.

    This press release contains certain forward-looking statements, within the meaning of Section 27A of the US Securities Act of 1933, as amended, Section 21E of the US Securities Exchange Act of 1934, as amended, and the safe harbor provisions of the US Private Securities Litigation Reform Act of 1995, with respect to the Company's business, financial condition and results of operations. We have based these forward-looking statements on our current expectations and projections about future events

    Words such as "believe," "anticipate," "expect," "intend," "will," "plan," "could," "may," "project," "goal," "target," and similar expressions often identify forward-looking statements but are not the only way we identify these statements. Except for statements of historical fact contained herein, the matters set forth in this press release regarding our future performance, plans to increase revenues or margins and any statements regarding other future events or future prospects are forward-looking statements.

    These forward looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those contemplated in such forward-looking statements, including, but not limited to:

    - the effect of the worldwide recession on our sales to our customers in the United States and in Europe and on our ability to finance our operations; - our customers' continued purchase of our products in the same volumes or on the same terms; - the failure of any of our principal customers to satisfy its payment obligations to us; - the cyclical nature of the clothing retail industry and the ongoing changes in fashion preferences; - the competitive nature of the markets in which we operate, including the ability of our competitors to enter into and compete in the seamless market in which we operate; - the potential adverse effect on our business resulting from our international operations, including increased custom duties and import quotas (e.g., in China, where we manufacture for our swimwear division) - fluctuations in inflation and currency rates; - the potential adverse effect on our future operating efficiency resulting from our expansion into new product lines with more complicated products, different raw materials and changes in market trends; - the purchase of new equipment that may be necessary as a result of our expansion into new product lines; - our dependence on our suppliers for our machinery and the maintenance of our machinery; - the fluctuations costs of raw materials; - our dependence on subcontractors in connection with our manufacturing process - our failure to generate sufficient cash from our operations to pay our debt; - political, economic, social, climatic risks, associated with international business and relating to operations in Israel;

    As well as certain other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

    TABLE 1: SALES BY SEGMENTS Three months ended Three months ended Year ended December March 31, 2010 March 31, 2009 31, 2009 USD USD USD Segment Thousands % of total Thousands % of total Thousands % of total Cut & sew 14,349 55.7% 25,334 53.9% 53,232 46.1% Seamless 11,424 44.3% 21,651 46.1% 62,306 53.9% Total 25,773 100.0% 46,985 100.0% 115,538 100.0% TABLE 2: SALES BY PRODUCT LINE Three months Three months Year ended ended March ended March December 31, 2010 31, 2009 31, 2009 Product line USD % of USD % of USD % of Thousands total Thousands total Thousands total Intimate Apparel 13,014 50.5% 20,017 42.6% 64,143 55.5% Active wear 2,329 9.0% 8,743 18.6% 21,533 18.6% Swimwear 10,430 40.5% 18,225 38.8% 29,862 25.8% Total 25,773 100.0% 46,985 100.0% 115,538 100.0% Swimwear growth -42.8% Intimate Apparel growth -35.0% Active wear -73.4% CONSOLIDATED BALANCE SHEETS U.S. dollars in thousands March 31, December 31, 2010 2009 2009 Unaudited Audited ASSETS CURRENT ASSETS: Cash and cash equivalents $ 326 $ 211 $ 1,904 Short-term investments 737 1,149 737 Trade receivables, net 14,974 30,595 14,597 Other accounts receivable and prepaid expenses 2,971 4,312 2,892 Inventories 21,348 26,026 19,778 Total current assets 40,356 62,293 39,908 NON- CURRENT ASSETS: Subordinated note - 2,400 - Deferred taxes, net 1,220 - 1,409 Property, plant and equipment, net 54,706 62,613 56,920 Intangible assets, net 857 1,921 960 56,783 66,934 59,289 Total assets $ 97,139 $ 129,227 $ 99,197 CONSOLIDATED BALANCE SHEETS U.S. dollars in thousands (except share and per share data) March 31, December 31, 2010 2009 2009 Unaudited Audited LIABILITIES AND SHAREHOLDERS' EQUITY CURRENT LIABILITIES: Short-term bank credit $ 2,971 $ 24,262 $ 25,847 Trade payables 18,215 24,769 15,042 Other accounts payable and accrued expenses 4,346 6,970 5,666 Total current liabilities 25,532 56,001 46,555 LONG-TERM LIABILITIES: Long term loans from banks (net of current maturities) 19,790 - - Other accounts payable 1,454 1,432 1,838 Accrued severance pay, net 648 1,413 729 Deferred taxes, net 1,906 6,688 3,080 Total long-term liabilities 23,798 9,533 5,647 SHAREHOLDERS' EQUITY: Share capital - Ordinary shares 10,351 7,518 7,518 Additional paid-in capital 108,782 107,161 107,522 Accumulated deficit (63,920) (43,594) (60,666) Less - 99,740 Ordinary shares in treasury, at cost (7,408) (7,408) (7,408) Other capital reserve 4 (231) 29 47,809 63,446 46,995 Employee stock options in subsidiary - 247 - Total shareholders' equity 47,809 63,693 46,995 Total liabilities and shareholders' equity $ 97,139 $ 129,227 $ 99,197 CONSOLIDATED STATEMENTS OF OPERATIONS U.S. dollars in thousands (except share and per share data) Year Three months ended ended December March 31, 31, 2010 2009 2009 Unaudited Audited Sales $ 25,773 $ 46,985 $ 115,538 Cost of sales 24,829 41,520 119,339 Gross profit (loss) 944 5,465 (3,801) Selling, general and administrative expenses 4,519 5,798 17,621 Other income - - (496) Operating loss (3,575) (333) (20,926) Loss from early repayment of subordinated note receivable - - (1,285) Financial expenses (income), net 538 (494) 512 Income (loss) before taxes on income (4,113) 161 (22,723) Taxes on income (tax benefit) (859) 16 (5,330) Net income (loss) $ (3,254) $ 145 (17,579) Basic and diluted net earnings (losses) per share: Basic net earnings (losses) per share $ (1.5) $ 0.1 $ (8.1) Diluted net earnings (losses) per share $ (1.5) $ 0.1 $ (8.1) Weighted average number of shares used for computing basic earnings (losses) per share 2,178,746 2,137,178 2,137,178 Weighted average number of shares used for computing diluted earnings (losses) per share 2,178,746 2,137,178 2,137,178 CONSOLIDATED STATEMENTS OF CASH FLOWS U.S. dollars in thousands Year Three months ended ended December March 31, 31, 2010 2009 2009 Unaudited Audited Cash flows from operating activities Net income (loss) $ (3,254) $ 145 $ (17,393) Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: Depreciation of property, plant and equipment and intangible assets 2,340 2,213 9,256 Compensation related to options granted to employees 70 57 171 Impairment reversal of property, plant and equipment and intangible assets - - (496) Inventory write-off 297 480 2,808 Extinguishment of contingent consideration against profit or loss - - (399) Change in employee benefit liabilities, net (81) (756) (850) Loss from early repayment of subordinated note receivable - - (75) Deferred taxes, net (985) (209) (5,364) Loss (gain) on disposal of property, plant and equipment - - 1,285 Decrease (increase) in trade receivables, net (377) (7,149) 8,849 Decrease (increase) in other accounts receivable and prepaid expenses (294) 499 1,497 Decrease (increase) in inventories (1,867) 5,619 9,730 Increase (decrease) in trade payables 3,173 (398) (10,125) Decrease in other accounts payable and accrued expenses (1,514) (1,052) (428) Net cash used in operating activities (2,496) (568) (1,476) Cash flows from investing activities Purchase of property, plant and equipment (22) (232) (611) Purchase of intangible assets (1) (26) (75) Contingent consideration paid - - (271) Proceeds from sale of property, plant and equipment 4 18 18 Proceeds from early repayment loss from subordinated note receivable - - 1,715 Net cash provided by (used in) investing activities (19) (240) 776 CONSOLIDATED STATEMENTS OF CASH FLOWS U.S. dollars in thousands Year Three months ended ended December March 31, 31, 2010 2009 2009 Unaudited Audited Cash flows from financing activities Short-term bank credit, net $ (11,275) $ 491 $ 4,923 Repayment of long-term bank loans (11,601) (1,038) (3,885) Proceeds from long-term bank loans 20,000 - - Issue of shares (net of issue expenses) 3,813 - - Net cash provided by (used in)financing activities 937 (547) 1,038 Increase (decrease) in cash and cash equivalents (1,578) (1,355) 338 Cash and cash equivalents at the beginning of the period 1,904 1,566 1,566 Cash and cash equivalents at the end of the period $ 326 $ 211 $ 1,904 Contacts Company Contact: Eran Rotem Chief Financial Officer +972-4-990-0881 reran@tefron.com

    Tefron Ltd

    CONTACT: Company Contact: Eran Rotem, Chief Financial Officer,
    +972-4-990-0881, reran@tefron.com




    Green Earth Technologies Has a New Ultimate Biodegradable Solution for the Gulf Oil Spill DisasterGreen Earth Technologies Has Submitted a 100% NON-TOXIC Solution to the EPA for Immediate Consideration & Use

    STAMFORD, Conn., May 21 /PRNewswire-FirstCall/ -- Green Earth Technologies (Pink Sheets: GETG) announced today that they have submitted G-Marine OSC-1809 Oil & Fuel Spill Clean-UP! to the EPA as a non-toxic dispersant option for immediate consideration to emulsify and remediate the oil spill in the Gulf of Mexico. The G-Marine Oil & Fuel Spill Clean-UP! brand is new to the marketplace and has recently been submitted to the EPA for approval, but all of the product's ingredients have passed DfE screening and may be found on DfE's Cleangredient list that confirms biodegradation and non-toxicity.

    (Photo: http://www.newscom.com/cgi-bin/prnh/20100521/NY08753 )

    The EPA has Given BP Officials 24 Hours to Choose a Less Toxic Chemical Dispersant. Green Earth Technologies has the capacity to meet EPA's requirements with a concentrated solution of G-Marine Oil & Fuel Spill Clean-UP!, made from a base of plant, tree, fruit and vegetable extracts processed into a colloidal micelle solution.

    "Due to the nature and urgency of this crisis, we believe that the EPA should waive the 60-90 day approval process, and consider any and all non-toxic alternatives that can meet the needs of the issue at hand," said Jeffrey Loch, Founder and CMO of Green Earth Technologies. "As all of the ingredients of the G-MARINE dispersant are already approved on the DfE's list, making them safe for direct to water release, the EPA should have confidence in our existing data and results allowing for on-site testing."

    Supporting this unique solution to the Gulf oil catastrophe is the Disaster Response Leadership Forum, a Washington-based independent organization which identifies the most effective disaster response solutions. Its Chairman - William Loiry - was instrumental in bringing thousands of government, business, and nonprofit leaders together to facilitate the short-term and long-term economic reconstruction of the U.S. Gulf Coast following Hurricanes Katrina and Rita. Loiry has recommended approval of the Green Earth Technologies non-toxic solution to BP CEO Tony Hayward.

    "BP has already expressed interest in G-MARINE and we urge the EPA to give their blessing to a new, but proven product as the chosen dispersant," said Jeff Marshall, Chairman & CEO of Green Earth Technologies. "As the oil reaches the environmentally sensitive Louisiana coastline, it is important to react immediately and we know G-MARINE Fuel Spill Clean-Up! will be the answer for this effort. The fact that this solution is non-toxic should also be good news to the millions of Americans now concerned about the safety of seafood in the Gulf of Mexico."

    Green Earth Technologies also has a plan in place with Corent Company, in cooperation with Evergreen Flying, Inc., both Louisiana based companies, to use 1295 hp Turbine Air Tractor aircraft to apply G-Marine Fuel Spill Clean-UP! dispersant over the affected areas of the BP/Trans Ocean Rig Collapse in the Gulf of Mexico. Utilizing 7 air tractor 802 aircraft, 14 square miles of oil spill could be treated daily.

    G-MARINE Fuel Spill Clean-UP! is a unique blend of plant derived, water based and ultimate biodegradable ingredients specifically formulated to quickly emulsify and encapsulate fuel and oil spills. These plant derived ingredients are processed to form a colloidal micelle whose small particle size (1-4 nanometers) enables it to penetrate and breakdown long chain hydrocarbons bonds in oils and grease and holds them in a colloidal suspension when mixed with water. Once oil has been suspended in a nano-colloidal suspension, there is no reverse emulsion; the oil becomes water soluble allowing it to be consumed by resident bacteria in the water. This dispersant formula is protected by trade secrets pursuant to Occupational Safety and Health Agency (OSHA) Standard CFR-1910 1200. The ingredient list has been reviewed by the US EPA and contains no ingredients considered hazardous by OSHA.

    ABOUT GREEN EARTH TECHNOLOGIES

    Green Earth Technologies produces G-branded superior performing green products made with American-grown base oils that utilize the power of nanotechnology to deliver environmentally friendly products with no compromise... meaning, consumers can now "do their part" without having to give up performance or value: Save the Earth - Sacrifice Nothing® is the Company's tagline. The G-brand family of products include G-OIL®, G-MARINE(TM), G-FUEL(TM), G-WASH(TM), G-GLASS(TM), G-CLEAN(TM), G-SCENT(TM), G-WHEEL(TM), and G-TIRE(TM), and are offered in a wide range of automotive categories including performance and appearance chemicals. GET products are now available at The Home Depot, Meijers, Kroger, Albertson's, Giant, Shop Rite, VIP, National Auto, Fred Meyer, participating ACE & True Value dealers, Redners, Trader Horns, The Andersons, Biggs, Bennett Auto, Frank's Auto Supermarket and Amazon.com. Please visit http://www.getg.com/ for the latest news and in-depth information about GET and its brands.

    Statements made in this release that relate to future plans, events, financial results or performance are forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995. These statements are based upon current information and expectations. Actual results may differ materially from those anticipated as a result of certain risks and uncertainties. Investors should also be aware that while the Company from time to time does communicate with securities analysts, it is against the Company's policy to disclose to them any material non-public information or other confidential commercial information. Investors should not assume that the Company agrees with any report issued by any analyst or with any statements, projections, forecasts or opinions contained in any such report.

    Contact: Courtney Jacobs Grey Alliance 212-546-2372 cjacobs@alliance-agency.com

    Photo: http://www.newscom.com/cgi-bin/prnh/20100521/NY08753
    PRN Photo Desk, photodesk@prnewswire.com Green Earth Technologies

    CONTACT: Courtney Jacobs, Grey Alliance, +1-212-546-2372,
    cjacobs@alliance-agency.com

    Web Site: http://www.getg.com/




    Borders Raises $25 Million Through Equity Financing to Support Key Financial and Strategic Initiatives

    ANN ARBOR, Mich., May 21 /PRNewswire-FirstCall/ -- Borders Group, Inc. today announced that an entity controlled by Bennett S. LeBow has agreed to invest $25 million in the company through a private purchase of 11.1 million shares of the company's common stock at a purchase price of $2.25 per share and on other terms described below. The investment -- coupled with the company's recently announced financing -- will strengthen Borders' balance sheet and provide capital to help fund the transformation of the Borders brand. Mr. LeBow's investment will support several important financial and strategic initiatives such as improving the company's capital position, addressing the store network to maximize productivity and profitability, maximizing the digital opportunity including growing Borders.com, and developing strategic business partnerships. The purchase is expected to close later today.

    (Logo: http://www.newscom.com/cgi-bin/prnh/20060208/BORDERSGRPLOGO )

    In connection with the investment, Mr. LeBow has joined the Board of Directors and has also been elected Chairman. Mr. LeBow is the Chairman of Vector Group, Ltd. . Howard Lorber, who serves as President and Chief Executive Officer of Vector Group, has also joined the Board of Directors of Borders Group.

    "Ben's investment will improve the company's capital position, and provide greater stability as we execute strategies to transform the brand," said Borders Group Interim President and Chief Executive Officer Mike Edwards. "Ben brings the right combination of skills, experience, focus and fresh perspective to his role as the new Chairman of the Board of Directors. As an astute investor and business operator with a strong technology background and proven experience with driving company turnarounds, he will play an extremely important role in helping us redefine the Borders brand that is so critical to unlocking a turnaround for Borders."

    Additionally, in order to create the nine-member Board as required by the terms of the transaction, Richard "Mick" McGuire has resigned from the Board of Directors.

    "I am pleased to welcome Ben aboard as the new Chairman," said McGuire. "Borders has made great progress in improving its financial and operating condition by exiting non-core businesses, reducing fixed costs, improving working capital efficiency, and focusing on operational excellence. More recently, the executive team has begun the process of repositioning the business and in-store experience to succeed in a future of electronic delivery. This effort is supported by an exceptional group of directors who were selected for the Board because of their expertise in the areas most critical to the company's success. By adding Ben and Howard to this already talented group, the company is now in the best possible position to achieve its full potential."

    Terms of the Equity Financing

    Borders Group has entered into a purchase agreement relating to the investment that, among other things, requires the company to seek approval from its shareholders for the issuance to Mr. LeBow of a stock purchase warrant exercisable to acquire an additional 35.1 million shares of the company's common stock at a price of $2.25 per share and for the issuance of the underlying 35.1 million warrant shares. The company expects to schedule a special meeting of its shareholders as soon as practicable to seek approval for the issuance of the warrant and warrant shares. If the issuance of the warrant and warrant shares is not approved by the company's shareholders, the company will be obligated to issue to Mr. LeBow 35.1 million stock appreciation rights. Upon the exercise of the stock appreciation rights, Borders Group would be required to make a cash payment with respect to each right equal to the excess, if any, of the future market price of the company's common stock over the $2.25 base price provided in the stock appreciation rights.

    Indicative Support from Pershing Square

    Pershing Square Capital Management, L.P. and its affiliates, which currently is a major shareholder of Borders Group, has indicated its support for the transaction. As a result of the purchase of common stock by Mr. LeBow, Borders Group will be required under the terms of its existing agreements with Pershing Square and its affiliates to issue Pershing Square approximately 2.7 million warrants exercisable at a price of $0.65 per share. Upon the issuance of the warrant or stock appreciation rights to Mr. LeBow, the company will be required to issue Pershing Square approximately an additional 8.6 million warrants at the same $0.65 per share exercise price.

    Rothschild Inc. served as financial advisor to Borders Group and Jefferies & Company, Inc. served as financial advisor to Mr. LeBow. Baker & McKenzie LLP represented Borders Group and Latham & Watkins LLP represented Mr. LeBow. Jones Day advised the Board of Directors of Borders Group in connection with the transaction.

    Details of the purchase agreement will be included in a Form 8-K to be filed promptly with the Securities and Exchange Commission.

    About Borders Group, Inc.

    Headquartered in Ann Arbor, Michigan, through its subsidiaries Borders Group, Inc. is a leading specialty retailer of books as well as other educational and entertainment items. The company employs approximately 19,500 throughout the U.S., primarily in its Borders® and Waldenbooks® stores. Online shopping is offered through borders.com. Find author interviews and vibrant discussions of the products we and our customers are passionate about online at facebook.com/borders, twitter.com/borders and youtube.com/bordersmedia. For more information about the company, visit borders.com/media.

    Safe Harbor Statement

    This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. One can identify these forward-looking statements by the use of words such as "expect," "planning," "possibility," "opportunity," "goal," "will," "may," "intend," "anticipates," "working toward" and other words of similar meaning. One can also identify them by the fact that they do not relate strictly to historical or current facts. These statements are likely to address matters such as the company's future financial condition and performance (including earnings per share, the profitability of Waldenbooks, liquidity, cash flows, debt levels, market share growth and other sales information, inventory levels and capital expenditures) and its strategic initiatives such as the expansion of product categories, including eBook content and eReaders. These statements are subject to risks and uncertainties that could cause actual results and plans to differ materially from those included in the company's forward-looking statements.

    These risks and uncertainties include, but are not limited to, consumer demand for the company's products, particularly during the holiday season, which is believed to be related to general economic and geopolitical conditions, competition and other factors; the availability of adequate capital - including vendor credit - to fund the company's operations and to carry out its strategic plans; adverse litigation results or other claims, the performance of the company's information technology systems and, with respect to eBook content and eReaders, the availability to the company of anticipated content levels and a variety of competitive devices.

    The company's periodic reports filed from time to time with the Securities and Exchange Commission contain more detailed discussions of these and other risk factors that could cause actual results and plans to differ materially from those included in the forward-looking statements, and those discussions are incorporated herein by reference. The company does not undertake any obligation to update forward-looking statements.

    Photo: http://www.newscom.com/cgi-bin/prnh/20060208/BORDERSGRPLOGO Borders Group, Inc.

    CONTACT: Investors, Mark Bierley, +1-734-477-4105; Media, Mary Davis,
    +1-734-477-1374

    Web Site: http://www.borders.com/media




    AerCap Signs Debt Facilities for Total of US$190 Million With Three Banks From Europe and Asia

    AMSTERDAM, May 21, 2010 /PRNewswire/ --

    AerCap Holdings N.V. ("AerCap"), (NYSE: AER) today announced that it has signed debt facility agreements totaling US$190 million. The facilities have terms ranging from eight to ten years and cover the financing of A319, A321 and A330 aircraft. The separate facilities were provided individually by Credit Agricole CIB, DBS Bank Singapore and Sumitomo Mitsui Banking Corporation (SMBC).

    AerCap's CFO, Keith Helming, said: "We are delighted to be expanding AerCap's broad network in the financial community with DBS Bank from Singapore, a new business partner for us, and to build up on our already strong relationships with Credit Agricole CIB and SMBC."

    Including the new facilities, AerCap has now closed US$560 million of new debt in 2010 which brings the total amount of debt accessed by the company in the last two years to US$5.5 billion.

    About AerCap Holdings N.V.

    AerCap is the world's leading independent aircraft leasing company. AerCap also provides engine leasing, aircraft management services, aircraft maintenance, repair and overhaul services and aircraft disassemblies. AerCap is headquartered in The Netherlands and has offices in Ireland, the United States, China, Singapore and the United Kingdom.

    This press release may contain forward-looking statements that involve risks and uncertainties. In most cases, you can identify forward-looking statements by terminology such as "may", "should", "expects", "plans", "anticipates", "believes", "estimates", "predicts", "potential" or "continue" or the negative of such terms or similar terminology. Such forward-looking statements are not guarantees of future performance and involve significant assumptions, risks and uncertainties, and actual results may differ materially from those in the forward-looking statements.

    Contact for Media: Contact for Investors: Frauke Oberdieck Peter Wortel +31-20-655-9616 +31-20-655-9658 foberdieck@aercap.com pwortel@aercap.com

    AerCap Holdings N.V.

    Media: Frauke Oberdieck, +31-20-655-9616, foberdieck@aercap.com, or Investors: Peter Wortel, +31-20-655-9658, pwortel@aercap.com, both of AerCap Holdings N.V.




    DuPont Titanium Technologies Announces a Price Increase for Ti-Pure(R) Titanium Dioxide Products in Europe, Middle East and Africa

    WILMINGTON, Delaware, May 21, 2010 /PRNewswire/ --

    DuPont Titanium Technologies announces a price increase for all DuPont(TM) Ti-Pure(R) titanium dioxide (TiO2) grades sold in Europe, Middle East, and Africa regions.

    Effective July 1, 2010, or as permitted by contract, net prices in the Euro markets of Western and Central Europe and North Africa regions will increase by 150 Euros per metric tonne. This is in addition to the previously announced June 1, 2010 increase.

    Effective July 1, 2010, or as permitted by contract, net prices in the U.S. dollar markets of Eastern Europe, Middle East and Sub-Saharan Africa regions will increase by $150 per metric tonne (USD). This is in addition to the previously announced June 1, 2010 increase.

    DuPont Titanium Technologies is the world's largest manufacturer of titanium dioxide, serving customers globally in the coatings, paper and plastics industries. The company operates plants at DeLisle, Miss.; New Johnsonville, Tenn.; Edge Moor, Del.; Altamira, Mexico; and Kuan Yin, Taiwan; all of which use the chloride manufacturing process. The company also operates a mine in Starke, Fla. Technical service centers are located in Paulinia, Brazil; Mexico City, Mexico; Mechelen, Belgium; Dzerzhinskiy, Russia; Kuan Yin, Taiwan; Ulsan, Korea; Shanghai, China; and Wilmington, Del., to serve the Latin American, European, Middle Eastern, Asian and North American markets.

    DuPont is a science-based products and services company. Founded in 1802, DuPont puts science to work by creating sustainable solutions essential to a better, safer, healthier life for people everywhere. Operating in approximately 80 countries, DuPont offers a wide range of innovative products and services for markets including agriculture and food; building and construction; communications; and transportation.

    The DuPont Oval Logo, DuPont(TM), The miracles of science(TM) and Ti-Pure(R) are registered trademarks or trademarks of DuPont or its affiliates.

    Contact: Kimberlie A. Lantz +1-302-999-2361 kimberlie.a.lantz@usa.dupont.com

    DuPont Titanium Technologies

    Kimberlie A. Lantz of DuPont, +1-302-999-2361, kimberlie.a.lantz@usa.dupont.com




    Oncothyreon announces presentations at American Society Of Clinical Oncology (ASCO) Annual Meeting

    SEATTLE, May 21 /PRNewswire-FirstCall/ -- Oncothyreon Inc. today announced that data highlighting the Company's two small molecule programs will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting being held June 4 through 8, 2010 in Chicago.

    Clinical data regarding Oncothyreon's product candidates PX-866 and PX-478 will be featured in the following poster presentations:

    Final Results from a Phase I Dose-Escalation Study of PX-866, an Irreversible, Pan-Isoform Inhibitor of PI3 Kinase (http://abstract.asco.org/AbstView_74_42490.html)

    Date/Location: Monday, June 7, 2010, 8:00 a.m. to 12:00 p.m., S Hall A2 Presenter: Antonio Jimeno, M.D., Ph.D., University of Colorado Cancer Center, Aurora, CO Abstract Number: 3089 (http://abstract.asco.org/AbstView_74_42490.html)

    Results from a Phase I Dose-Escalation Study of PX-478, an Orally Available Inhibitor of HIF-1alpha (http://abstract.asco.org/AbstView_74_42538.html)

    Date/Location: Monday, June 7, 2010, 8:00 a.m. to 12:00 p.m., S Hall A2 Presenter: Raoul Tibes, M.D, Ph.D., Virginia G. Piper Cancer Center and TGen, Scottsdale, AZ Abstract Number: 3076 (http://abstract.asco.org/AbstView_74_42538.html) About Oncothyreon

    Oncothyreon is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer. Oncothyreon's goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes of cancer patients. For more information, visit http://www.oncothyreon.com/.

    Oncothyreon Inc.

    CONTACT: Investor and Media Relations Contact: Julie Rathbun, Rathbun
    Communications, (206) 769-9219, ir@oncothyreon.com




    DuPont Titanium Technologies Announces a Price Increase for Ti-Pure® Titanium Dioxide Products in Europe, Middle East and Africa

    WILMINGTON, Del., May 21 /PRNewswire/ -- DuPont Titanium Technologies announces a price increase for all DuPont(TM) Ti-Pure® titanium dioxide (TiO2) grades sold in Europe, Middle East, and Africa regions.

    Effective July 1, 2010, or as permitted by contract, net prices in the Euro markets of Western and Central Europe and North Africa regions will increase by 150 Euros per metric tonne. This is in addition to the previously announced June 1, 2010 increase.

    Effective July 1, 2010, or as permitted by contract, net prices in the U.S. dollar markets of Eastern Europe, Middle East and Sub-Saharan Africa regions will increase by $150 per metric tonne (USD). This is in addition to the previously announced June 1, 2010 increase.

    DuPont Titanium Technologies is the world's largest manufacturer of titanium dioxide, serving customers globally in the coatings, paper and plastics industries. The company operates plants at DeLisle, Miss.; New Johnsonville, Tenn.; Edge Moor, Del.; Altamira, Mexico; and Kuan Yin, Taiwan; all of which use the chloride manufacturing process. The company also operates a mine in Starke, Fla. Technical service centers are located in Paulinia, Brazil; Mexico City, Mexico; Mechelen, Belgium; Dzerzhinskiy, Russia; Kuan Yin, Taiwan; Ulsan, Korea; Shanghai, China; and Wilmington, Del., to serve the Latin American, European, Middle Eastern, Asian and North American markets.

    DuPont is a science-based products and services company. Founded in 1802, DuPont puts science to work by creating sustainable solutions essential to a better, safer, healthier life for people everywhere. Operating in approximately 80 countries, DuPont offers a wide range of innovative products and services for markets including agriculture and food; building and construction; communications; and transportation.

    The DuPont Oval Logo, DuPont(TM), The miracles of science(TM) and Ti-Pure® are registered trademarks or trademarks of DuPont or its affiliates.

    Contact: Kimberlie A. Lantz 302-999-2361 kimberlie.a.lantz@usa.dupont.com

    DuPont Titanium Technologies

    CONTACT: Kimberlie A. Lantz of DuPont, +1-302-999-2361,
    kimberlie.a.lantz@usa.dupont.com

    Web Site: http://www.titanium.dupont.com/




    PLC Medical Systems to Demonstrate RenalGuard® at EuroPCR 2010Company to Hold First International Distributor Meeting as Part of Program

    FRANKLIN, Mass., May 21 /PRNewswire-FirstCall/ -- PLC Systems Inc. (OTC Bulletin Board: PLCSF), a company focused on innovative cardiac and vascular medical device-based technologies, today announced that it will demonstrate RenalGuard® at EuroPCR, the annual meeting of the European Association of Percutaneous Cardiovascular Interventions (EAPCI), May 25-28, 2010, in Paris, France. More than 11,000 clinicians and professionals are expected to attend this event.

    In addition, PLC will hold its first international distributor meeting, including a presentation on the status of the MYTHOS investigator-sponsored clinical trial by Dr. Antonio Bartorelli, one of the two principal investigators of the trial.

    Mark R. Tauscher, president and chief executive officer of PLC Systems, said, "EuroPCR is one of the premier international cardiovascular events of the year. Since RenalGuard could provide an important solution for patients with diminished kidney function undergoing cardiac imaging procedures, this conference gives us a strong opportunity to meet with global knowledge leaders, current and potential customers, and current and potential distributors. Our first international distributor meeting, to be held in concert with EuroPCR, provides us with an important opportunity to further educate our distribution partners about the latest scientific findings on RenalGuard's safety and efficacy, which we hope accelerates adoption of RenalGuard in the countries where it is now being marketed."

    PLC recently received Notices of Allowance for four of PLC's patent applications associated with its RenalGuard technology from the U.S. Patent and Trademark Office. The company has distribution agreements covering Austria; Croatia; Russia; Belgium; the Netherlands; Luxembourg; all of the former Soviet Socialist Republic nations; Portugal; New Zealand; Portugal; China and Taiwan; Italy; Spain; Monaco; Pakistan and Bangladesh.

    About PLC Systems Inc.

    PLC Systems Inc. is a medical technology company specializing in innovative technologies for the cardiac and vascular markets. Headquartered in Franklin, Massachusetts, PLC pioneered the CO2 Heart Laser System, which cardiac surgeons use to perform CO2 transmyocardial revascularization (TMR) to alleviate symptoms of severe angina. PLC's newest product, RenalGuard, is approved for sale in the EU as a general fluid balancing device. Additional company information can be found at http://www.plcmed.com/.

    This press release contains "forward-looking" statements. For this purpose, any statements contained in this press release that relate to prospective events or developments are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will" and similar expressions are intended to identify forward-looking statements. Our statements of our objectives are also forward-looking statements. While we may elect to update forward-looking statements in the future, we specifically disclaim any obligation to do so, even if our estimates change, and you should not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release. Actual results could differ materially from those indicated by such forward-looking statements as a result of a variety of important factors, including that we may be unable to raise capital necessary to continue our operations, we may not receive necessary regulatory approvals to market our RenalGuard product or that such approvals may be withdrawn, the current clinical trials in Italy and the planned future U.S. clinical trial for RenalGuard may not be completed in a timely fashion, if at all, or, if these clinical trials are completed, they may not produce clinically significant or meaningful results, the RenalGuard product may not be commercially accepted, operational changes, competitive developments may affect the market for our products, regulatory approval requirements may affect the market for our products, and additional risk factors described in the "Forward Looking Statements" section of our Annual Report on Form 10-K for the year ended December 31, 2009, and our other SEC reports.

    PLC Systems, PLC Medical Systems, PLC, CO2 Heart Laser, and RenalGuard are trademarks of PLC Systems Inc.

    Contact: Mary T. Conway Conway Communications 617-244-9682 mtconway@att.net

    PLC Systems

    CONTACT: Mary T. Conway of Conway Communications, +1-617-244-9682,
    mtconway@att.net, for PLC Systems

    Web Site: http://www.plcmed.com/




    Blur(TM) Features Innovative In-Game Facebook(R) IntegrationBizarre Creations' Powered-up Racer Allows Players to Connect with Friends Through Facebook Straight from the Game's Unique 'Share' Functionality

    SANTA MONICA, Calif., May 21 /PRNewswire-FirstCall/ -- Activision Publishing, Inc.'s highly-anticipated racing title Blur(TM) will deliver a new level of social interaction to gamers later this month by allowing fans to challenge their friends and share achievements directly from inside the game through Facebook.

    By seamlessly integrating an innovative "Share" button, Blur lets players choose to light up the competition in both single and multi-player modes by sending game challenges to friends and posting in-game photos, racing stats, unlockable items and much more on their Facebook pages.

    "Blur's innovative integration with Facebook makes it easy for players to interact with their real friends to share game play, emotions, and the racing experience," said Dan Rose, Vice President of Partnerships and Platform Marketing, Facebook. "Blur is leading the next generation of console games integrating with Facebook to make gaming more social for our more than 400 million users."

    "Blur is the first multi-platform videogame that connects the television to Facebook, and for the first time, videogame audiences on the Xbox 360, PlayStation 3 and PC will be able to link their console gameplay to their network of friends," said Robert Kotick, CEO, Activision Blizzard. "Facebook has become a fantastic platform for videogames and Blur elevates it even further."

    Blur is the ultimate powered-up racing experience, where players collect addictive and intense Power-ups throughout each course, including the ability to blast other cars out of the way with huge bursts of energy, boost speed with Nitros, drop Mines and even generate defensive shields to fend off other racers. Blur offers online multiplayer supporting competitive and cooperative gameplay for up to 20 racers, including team racing and objective based events, and also supports 4-player split-screen. For more information on Blur, please visit the official game web site located at http://www.blurthegame.com/, and check-out Blur on Facebook at http://www.facebook.com/blurthegame.

    Blur is scheduled for release nationwide May 25th for the Xbox 360® video game and entertainment system from Microsoft, PLAYSTATION®3 computer entertainment system, and the PC, and is rated "E10+" by the ESRB.

    About Bizarre Creations

    Bizarre Creations is a video game developer based in Liverpool, England. Established in 1994, the company is famed for such high profile franchises as Formula 1, Fur Fighters, Geometry Wars, The Club, and the Project Gotham Racing series. With 200+ staff working out of a custom-built development studio, the company now simultaneously develops several next-gen projects across various platforms. They can be found online at http://www.bizarrecreations.com/.

    About Activision Publishing, Inc.

    Headquartered in Santa Monica, California, Activision Publishing, Inc. is a leading worldwide developer, publisher and distributor of interactive entertainment and leisure products.

    Activision maintains operations in the U.S., Canada, the United Kingdom, France, Germany, Ireland, Italy, Sweden, Spain, Norway, Denmark, the Netherlands, Australia, Russia, Japan, South Korea, China and the region of Taiwan. More information about Activision and its products can be found on the company's website, http://www.activision.com/.

    Cautionary Note Regarding Forward-looking Statements: Information in this press release that involves Activision Publishing's expectations, plans, intentions or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. Activision Publishing generally uses words such as "outlook," "will," "could," "would," "might," "remains," "to be," "plans," "believes," "may," "expects," "intends," "anticipates," "estimate," future," "plan," "positioned," "potential," "project," "remain," "scheduled," "set to," "subject to," "upcoming" and similar expressions to identify forward-looking statements. Factors that could cause Activision Publishing's actual future results to differ materially from those expressed in the forward-looking statements set forth in this release include, but are not limited to, sales levels of Activision Publishing's titles, shifts in consumer spending trends, the impact of the current macroeconomic environment, the seasonal and cyclical nature of the interactive game market, Activision Publishing's ability to predict consumer preferences among competing hardware platforms, declines in software pricing, product returns and price protection, product delays, retail acceptance of Activision Publishing's products, adoption rate and availability of new hardware (including peripherals) and related software, industry competition, rapid changes in technology, industry standards and consumer preferences, protection of proprietary rights, litigation against Activision Publishing, maintenance of relationships with key personnel, customers, licensees, licensors, vendors and third-party developers, counterparty risks relating to customers, licensees, licensors and manufacturers, domestic and international economic, financial and political conditions and policies, foreign exchange rates and tax rates, integration of recent acquisitions and the identification of suitable future acquisition opportunities, and the other factors identified in the risk factors section of Activision Blizzard's most recent annual report on Form 10-K and any subsequent quarterly reports on Form 10-Q. The forward-looking statements in this release are based upon information available to Activision Publishing and Activision Blizzard as of the date of this release, and neither Activision Publishing nor Activision Blizzard assumes any obligation to update any such forward-looking statements. Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of Activision Publishing or Activision Blizzard and are subject to risks, uncertainties and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations.

    Activision is a registered trademark and Blur is a trademark of Activision Publishing, Inc. All rights reserved. Microsoft, Xbox, Xbox 360, Xbox LIVE, and the Xbox logos are trademarks of the Microsoft group of companies. "PlayStation", "PLAYSTATION", and "PS" Family logo are registered trademarks of Sony Computer Entertainment Inc. Facebook® is a registered trademark of Facebook Inc. All other trademarks and trade names are the properties of their respective owners.

    Activision Publishing, Inc.

    CONTACT: Paul Murphy, Senior Publicist of Activision Publishing, Inc.,
    +1-310-496-5241, Paul.Murphy@Activision.com

    Web Site: http://www.activision.com/




    Annual Welcome Back Awards Program Honors Individuals for Tremendous Contributions to the Depression Community-- Six Honorees will be recognized for their Achievements at 12th Annual Ceremony in New Orleans --

    INDIANAPOLIS, May 21 /PRNewswire-FirstCall/ -- Despite years of debilitating depression, multiple psychiatric hospitalizations and episodes of homelessness, Joseph Rogers refused to let mental illness and an unlucky adolescence blot out his potential imprint on the world. Despite once being branded unemployable, Joseph relishes his role as advocate, embracing the challenges of being a change agent in mental health legislation, and pioneering the peer-run services movement. Joseph Rogers' efforts have fundamentally changed the mental healthcare system--a system that had written him off many years ago - to better serve and assist those suffering from serious mental health challenges.

    Joseph is one of this year's six Welcome Back Award honorees who have conquered diverse challenges to improve the lives of others. "This year's honorees radiate hope to those with mental illness - the message that there are people who do understand their struggles and will do everything in their power to help," said Dr. Saundra Jain, Psy.D., MBA, LPC, a member of the awards selection committee and executive director of the Mental Health Educational Initiative in Lake Jackson, TX.

    "Each individual uses their unique talents to positively effect change in the mental health community," said Dr. Jain. "Through filmmaking, natural disaster relief and championing gender-specific research, the Welcome Back Award honorees truly deserve recognition for their influential work."

    Eli Lilly and Company will be honoring these inspiring winners at the 12th Annual Welcome Back Awards ceremony in New Orleans, LA, on Saturday, May 22. Lilly established the Welcome Back Awards in 1998 to fight the stigma associated with depression and to promote the understanding that depression is treatable. Each year, an independent panel of national mental health leaders recognizes individuals for their outstanding achievements, and Lilly awards donations ranging between $10,000 and $15,000 to the not-for-profit organization of each winner's choice.

    The 2010 Welcome Back Awards honorees are: Lifetime Achievement - Joseph A. Rogers, Philadelphia, PA

    Joseph Rogers is Chief Advocacy Officer (CAO) of the Mental Health Association of Southeastern Pennsylvania (MHASP) and executive director of the National Mental Health Consumers' Self-Help Clearinghouse. Joseph founded Project SHARE (Self-Help and Advocacy Resource Exchange) with support from MHASP and helped design Community Behavioral Health (CBH), a city-run agency in Philadelphia that administers $350 million annually to provide mental health and substance abuse services for 400,000 people receiving Medicaid. Through Project SHARE, he developed the Clearinghouse as a national peer-run assistance center that helps people across the country learn how to start and maintain self-help groups and improve mental health. His advocacy efforts also led to the Philadelphia Police Department's adoption of the award-winning Crisis Intervention Team model, which has been proven to prevent injuries and save the lives of police officers and civilians citywide. Most notably, Joseph has built MHASP from a 12-person regional agency into a multi-faceted organization with more than 300 staff members -- now one of the largest mental health associations in the United States.

    Destigmatization - Annie Sundberg and Ricki Stern, New York, NY

    Ricki Stern and Annie Sundberg's passion for social issues and filmmaking led them to direct and produce the films "More Than Sad: Teen Depression" and "More Than Sad: Preventing Teen Suicide," in association with the American Foundation for Suicide Prevention. Almost 5,000 copies of the films have been distributed to high schools across the U.S., helping students, educators and counselors become more adept at recognizing the signs of depression and identifying possible treatment options for teens who might be at risk for suicide. With the difficult challenge of creating an accurate representation of the feelings teens experience while minimizing the risk of imitation, the films successfully promote the idea that depression is an illness and help erase the stigma that's so often associated with the illness. Annie and Ricki bring realistic stories of depression and despair to life, fostering open communication in school systems about ways to find help when teenagers are feeling embarrassed, confused and alone.

    Primary Care - Trinidad de Jesus Arguello, Ph.D., LISW, RN, Arroyo, NM

    Trinidad de Jesus Arguello, a clinical social worker, psychiatric nurse and author, has dedicated the past 33 years of her life to the field of mental health with a particular focus on domestic abuse and depression in women. She is currently the program director for Tri-County Community Services, Inc., where she has effectively brought together a strong team of professionals that delivers crucial in-home mental health services to residents of Taos, NM, in need of crisis intervention. Dr. Arguello has directed several cultural advisory groups and community and behavior health programs including the National Alliance on Mental Illness (NAMI) affiliate in Taos, which she started herself. She also provided much-needed front-line mental health treatment to the victims of Hurricane Katrina. The breadth of Dr. Arguello's work exemplifies her dedication to finding individualized treatment models and helping communities that face challenges such as poverty, cultural alienation, displacement, domestic abuse, unemployment and depression.

    Psychiatry - Susan G. Kornstein, M.D., Richmond, VA

    Susan Kornstein is a professor of Psychiatry and Obstetrics and Gynecology at Virginia Commonwealth University (VCU) and co-founder and executive director of the VCU Institute for Women's Health, a designated National Center of Excellence in Women's Health by the U.S. Department of Health and Human Services. Among her many accomplishments, Dr. Kornstein serves as an internationally recognized researcher in the areas of depression, anxiety disorders, premenstrual syndrome and sexual dysfunction. She edited the first comprehensive textbook ever on women's mental health and has worked to bring mental health professionals together from around the world in an extraordinary effort to advance the field of women's mental health. Dr. Kornstein has gone above and beyond typical mental health treatment by focusing on understanding and connecting the physical and psychiatric needs of women, and providing them with much-needed support during life's difficult transitions.

    Community Service - Danielle N. Butin, MPH, OTR, Yonkers, NY

    Danielle Butin is founder and executive director of the Afya Foundation of America, a large-scale medical supply recovery organization that works with major hospital systems to gather unused or overstocked supplies and sends them to well-established health organizations in Africa and the Caribbean. Through Afya, Danielle has created volunteer and pre-vocational training programs for individuals suffering from mental illness, which help give them meaning and purpose amidst their struggle and integrate them back into the community. In partnership with New York University and Columbia University, Danielle has also established Afya as a fieldwork training site for behavioral health and occupational therapy graduate students, allowing them to design individualized treatment models for the organization's volunteers. Danielle recently returned from Haiti where she sent a rehabilitation team of occupational and physical therapists along with several containers of vital medical supplies.

    "For the twelfth consecutive year, the Welcome Back Awards continue to serve as an inspiration to both people suffering from mental illness and mental healthcare providers," said Dr. John Hayes, M.D., senior director of Global Neuroscience Medical Affairs, Eli Lilly and Company. "The program brings to light new and creative approaches to improving mental health along with stories of hope and survival from truly courageous, altruistic individuals. The honorees' abilities to make a difference are something we should all strive for."

    Nominations for the 2011 Welcome Back Awards

    Nominations for the 2011 Welcome Back Awards may be submitted by anyone wishing to be recognized for his or her outstanding achievements in the depression community or wishing to recognize someone else. For more information, visit http://www.lilly.com/responsibility/servingpatients/outcomes/.

    About Lilly

    Lilly, a leading innovation-driven corporation is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers - through medicines and information - for some of the world's most urgent medical needs. Additional information about Lilly is available at http://www.lilly.com/.

    (Logo: http://photos.prnewswire.com/prnh/20090515/DE16982LOGO)

    O-LLY

    Photo: AP Archive: http://photoarchive.ap.org/
    http://photos.prnewswire.com/prnh/20090515/DE16982LOGO
    PRN Photo Desk, photodesk@prnewswire.com Eli Lilly and Company

    CONTACT: Julie Bernstein of Chamberlain Healthcare Public Relations,
    +1-212-884-0681, jbernstein@chamberlainpr.com

    Web Site: http://www.lilly.com/




    China TransInfo to Hold Annual Meeting of Stockholders in Beijing

    BEIJING, May 21 /PRNewswire-Asia-FirstCall/ -- China TransInfo Technology Corp., , ("China TransInfo" or the "Company"), a leading provider of public transportation information systems technology and comprehensive solutions in the People's Republic of China ("PRC"), today announced that it will hold its annual meeting of stockholders on Friday, June 11, 2010 in Beijing.

    The time and venue for China TransInfo's annual meeting of stockholders are as follows:

    Date: June 11, 2010 Time: 9:00 a.m. Beijing Time Venue: Vision Building, 9th Floor No. 39 Xueyuanlu, Haidian District, Beijing, PRC 100191.

    At the annual meeting of stockholders, the following proposals will be submitted for stockholder approval and are fully described in the Proxy Statement filed with the Securities and Exchange Commission on May 10, 2010. The Company's proxy and annual report are also available for download on the Company's corporate website: http://tinyurl.com/ctfoproxyandannualreport .

    1) electing seven directors to the Board of Directors of the Company;; 2) ratifying the Company's selection of BDO China Li Xin Da Hua CPAs Co., Ltd ("BDO China Li Xin"), a member firm of BDO Seidman, LLP, as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2010; and 3) such other business as may properly come before the Annual Meeting and any adjournments or postponements thereof.

    Shareholders of record as of April 26, 2010 are entitled to vote at the annual meeting of stockholders.

    About China TransInfo

    China TransInfo, through its affiliate, China TransInfo Technology Group Co., Ltd., (the "Group Company") and the Group Company's PRC operating subsidiaries, is primarily focused on providing transportation information services and comprehensive solutions based on Geographic Information System (GIS) technologies. The Company aims to become the largest transportation information products and comprehensive solutions provider, as well as the largest real time transportation information platform operator and provider in China. In addition, the Company is developing its transportation system to include Electronic Toll Collection technology. As the co-formulator of several transportation technology national standards, the Company owns software copyrights for 89 software products and has won 5 of the 10 model cases sponsored by the PRC Ministry of Communications. The Company's affiliation with Peking University provides the Company access to the University's GeoGIS Research Laboratory, including over 30 Ph.D. researchers. As a result, the Company is playing a key role in setting the standards for electronic transportation information solutions. For more information, please visit the Company's website at http://www.chinatransinfo.com/ .

    Safe Harbor Statement

    This press release contains certain statements that may include "forward looking statements". All statements other than statements of historical fact included herein are "forward-looking statements". These forward looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions, involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on its website ( http://www.sec.gov/ ). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

    For more information, please contact: Company Contact: Ms. Fan Zhou, Investor Relations Director China TransInfo Technology Corp. Email: ir@ctfo.com Tel: +86-10-5169-1657 Investor Relations Contact: CCG Investor Relations Mr. Athan Dounis, Account Manager Email: athan.dounis@ccgir.com Tel: +1-646-213-1916 Mr. Crocker Coulson, President Email: crocker.coulson@ccgir.com Tel: +1-646-213-1915 Website: http://www.ccgirasia.com/

    China TransInfo Technology Corp.

    CONTACT: Ms. Fan Zhou, Investor Relations Director of China TransInfo
    Technology Corp., ir@ctfo.com, +86-10-5169-1657; or Athan Dounis, Account
    Manager, athan.dounis@ccgir.com, +1-646-213-1916, or Crocker Coulson,
    President, crocker.coulson@ccgir.com, +1-646-213-1915, both of CCG Investor
    Relations

    Web site: http://www.chinatransinfo.com/
    http://tinyurl.com/ctfoproxyandannualreport




    AIVtech Retains CCG Investor Relations

    SHENZHEN, China, May 21 /PRNewswire-Asia-FirstCall/ -- AIVtech Holding (Hong Kong) Limited ("AIVtech" or the "Company"), a wholly-owned subsidiary of Ecochild, Inc. (BULLETIN BOARD: ECOH) announced today that it has retained CCG Investor Relations to design and execute its investor relations campaign. Through its subsidiaries, AIVtech designs, manufactures and markets electronic furniture, digital/multimedia speakers, and LCD/LED televisions.

    "We look forward to working with CCG to establish a more effective and transparent communications channel with the global investment community," said Mr. JinLin Guo, Chairman and CEO of AIVtech. "By leveraging CCG's international platform, extensive investor network and expertise, we are committed to active and transparent communications in order to raise our profile and improve investors' understanding of our business strategy and investment outlook. We expect to benefit from strong overseas demand for our high-quality, innovative products to advance the AIVtech brand name in the international marketplace. We're also well positioned to expand our market share by intensifying our focus on delivering superior and innovative products to our customers. We will work diligently to reach our goals of expanding our distribution coverage overseas to become a leading global consumer-electronics company."

    AIVtech is a fast-growing manufacturer of high-quality electronic furniture, multimedia speakers and LED televisions. The company's 2009 revenues derived solely from the sales of electronic furniture and digital/multimedia speakers. In April 2010, the Company began production of LED-backlit LCD televisions. For the year ended December 31, 2009, AIVtech reported revenues of $38.5 million, representing 85.4% growth from $20.7 million in 2008. Full-year 2009 net income was $7.5 million, an increase of 91.9% over 2008 net income of $3.9 million.

    "We are excited to be working with a client with unique technology, innovative products, and an extensive global reach," said Crocker Coulson, President of CCG. "AIVtech has broad global coverage, and the Company has been recognized as a distinguished manufacturer by its customers in North America, Europe, Southeast Asia, Australia and China. AIVtech differentiates itself from industry peers through its strong brand and strategy for international expansion. We are confident that AIVtech will continue to deliver innovative and quality products as well as maintain effective communications with investors."

    About AIVtech

    AIVtech is the parent company of wholly owned Shenzhen AIVtech Company Limited ("Shenzhen AIVtech"), which owns 70% of Dongguan AIVtech Company Limited ("Dongguan AIVtech"). AIVtech founder, Chairman, and CEO JinLin Guo owns the remaining 30% of Dongguan AIVtech. Founded in 2004, the company has focused on the integration of electronic products, such as multimedia speakers, video games, etc. with furniture and has coined the term "electronic furniture" to describe its products. The Company has three major product categories: (1) electronic furniture, including video chairs with built-in speakers and vibration, as well as leisure furniture with built-in audio/video systems; (2) multimedia/digital speakers; and (3) LCD/LED televisions. For more information, visit http://www.aivtech.com/ .

    About CCG Investor Relations

    CCG is a leading global investor relations and strategic communications consulting firm. In business for more than 30 years, the agency provides a complete range of investor communications, counseling, and IT and data solutions through our global network to over 300 clients across multiple capital markets. CCG has been awarded a number of industry honors for its handling of complex investor relations and crisis communications matters. The agency is headquartered in Los Angeles and has additional offices in New York, Beijing, Shanghai, Hong Kong, Frankfurt, Sao Paulo and Tel Aviv. For further information, contact CCG directly, or visit the Company's web sites at http://www.ccgir.com/ and http://www.ccgirasia.com/ .

    Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

    Statements contained in this press release, which are not historical facts, are forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based largely on current expectations and are subject to a number of known and unknown risks, uncertainties and other factors beyond our control that could cause actual events and results to differ materially from these statements. These statements are not guarantees of future performance, and readers are cautioned not to place undue reliance on these forward-looking statements, which are relevant as of the date of the given press release and should not be relied upon as of any subsequent date. AIVtech undertakes no obligation to update publicly any forward-looking statements.

    For more information, please contact: Company Contact: Mr. Terry Liao, Vice President AIVtech Group Co., Ltd. Tel: +86-755-8835-3133 Email: terryliao@aivtechgroup.com Investor Relations Contact: Mr. John Harmon, Sr. Account Manager CCG Investor Relations Tel: +1-646-833-3424 Email: john.harmon@ccgir.com

    AIVtech Holding (Hong Kong) Limited

    CONTACT: Company Contact: Terry Liao, Vice President, +86-755-8835-3133,
    terryliao@aivtechgroup.com, of AIVtech Group Co., Ltd.; Investor Relations
    Contact: John Harmon, Sr. Account Manager, +1-646-833-3424,
    john.harmon@ccgir.com, of CCG Investor Relations for AIVtech Group Co., Ltd.

    Web site: http://www.aivtech.com/
    http://www.ccgirasia.com/




    China BCT Reports First Quarter 2010 Results

    LIUZHOU CITY, Guangxi, China, May 21 /PRNewswire-Asia-FirstCall/ -- China BCT Pharmacy Group, Inc., (BULLETIN BOARD: CNBI) , ("China BCT" or the "Company"), a leading pharmaceutical distributor, retail pharmacy, and manufacturer of pharmaceutical products in Guangxi Province, China, today announced results for the first quarter ended March 31, 2010.

    First Quarter 2010 Highlights -- Revenue increased 5.2% to $34.0 million year over year -- Gross profit was up slightly year over year to $8.9 million -- Operating income decreased 11.5% to $6.2 million year over year -- GAAP net income was $4.2 million in the 2010 first quarter as compared to $5.0 million in the year ago quarter -- Excluding the non-cash, non-operating charge related to change in the fair value of warrant liabilities, non-GAAP adjusted net income was $4.5 million

    "While we grew sales by leveraging our strong relationships with suppliers and customers, a shift in product mix and significant investments in staffing and marketing negatively affected our profit in the first quarter," commented Mr. Hui Tian Tang, Chairman and Chief Executive Officer of China BCT Pharmacy Group, Inc. "We expect that these strategic investments in our business will return substantial gains over time. As the Chinese government's health care reforms expand, we are already seeing a growing number of our medi-care pharmacy customers receiving state health insurance coverage. Further, our recent acquisition of 48 retail pharmacy stores in Guangxi Province has further expanded our retail footprint to strengthen our leadership in the region and create new growth drivers in the coming quarters."

    First Quarter 2010 Results

    For the first quarter ended March 31, 2010, revenue increased 5.2% to $34.0 million, as compared to $32.3 million in the same quarter of 2009. The increase in revenue was primarily driven by a 29.0% increase in retail pharmacy sales, reflecting increased marketing campaigns that boosted existing store sales and contribution from new stores which opened in the second half of 2009. Pharmaceutical distribution revenues fell slightly to $23.2 million year-over-year, with a 24.3% growth in hospital sales offset by lower distributor sales. Lower distribution sales primarily reflect a shift in the Company's focus to sell directly to hospitals and the timing of orders from distributors in the first quarter of 2010. In future quarters, the Company anticipates accelerating revenue growth in the distribution segment to be driven by increased contribution from direct sales to hospitals and the consolidation of the recently acquired 48 retail pharmacy stores.

    In terms of revenue mix, wholesale distribution accounted for 68.2% of the total, while the retail pharmacy and manufacturing pharmacy contributed 26.1% and 5.7%, respectively, as compared to 72.6% from pharmaceutical distribution, 21.3% from retail pharmacy and 6.1% from manufacturing pharmacy for the first quarter of 2009.

    Gross profit was $8.9 million, compared to $8.8 million for the same period of 2009. Gross margin fell to 26.0%, as compared to 27.4% in the comparable period last year. Lower gross margin in the first quarter of 2010 mainly reflected a change in the Company's distribution portfolio that included a more diversified product mix, which is expected to drive sales volume and gross profit dollar growth over time.

    Operating expenses increased by 43.9% to $2.7 million, as compared to $1.9 million in the same period last year. Administrative expenses increased 64.9% to $1.6 million, as compared to $1.0 million in the same period of 2009, primarily due to an increase in staff compensation, including year-end bonuses, and rental expenditures. Administrative costs are expected to decline during the remainder of 2010. Selling expenses rose 19.5% to $1,026,519, compared to $858,686 in the same period of 2009, due to increased marketing activities to expand and gain additional market opportunities.

    Operating income declined 11.5% to $6.2 million, or 18.2% of revenue, from $7.0 million, or 21.6% of revenue, in the first quarter of 2009.

    GAAP net income fell to $4.2 million, or $0.11 per diluted share, as compared to $5.0 million, or $0.16 per diluted share, in the first quarter of 2009. Adjusted net income, excluding the $0.3 million non-cash expense related to change in the fair value of warrant liabilities, was $4.5 million, or $0.12 per diluted share. There were no comparable adjustments to net income in the first quarter of 2009.

    Financial Condition

    As of March 31, 2010, BCT had $13.0 million in cash and cash equivalents and $35.0 million in working capital and a current ratio of 1.9:1x. Long-term bank debt was $3.6 million. Shareholders' equity was $58.1 million on March 31, 2010, up from $53.4 million at the end of 2009.

    The Company generated $3.9 million in cash from operating activities for the quarter ended March 31, 2010, an increase compared to cash used in operating activities of $4.1 million in the same period in 2009. The increase in cash flow from operating activities primarily reflected decrease in trade receivables and increase in accounts payable and better cash management. Inventory level increased quarter-over-quarter as the Company anticipated accelerating revenue growth in future quarters.

    Recent Events

    In May 2010, China BCT announced that it acquired 48 retail pharmacy stores in two separate transactions. First, the Company acquired 30 retail pharmacy stores from a retail pharmacy operator in Liuzhou City for $2.4 million in cash from Wubaitang, a local pharmaceutical company with pharmaceutical wholesale and retail divisions, in March 2010. Management expects these newly acquired stores to contribute approximately $3.7 million to the Company's revenue in 2010. Subsequently, in April 2010, the Company acquired an 18-store retail pharmacy chain in Zhaoping County, the administrative region of Hezhou City, for $1.3 million in cash from Zhaoping Laobaixing Pharmacy Retail Limited, a local retail pharmaceutical chain store enterprise. The Company estimates that these 18 stores will contribute approximately $1.8 million to annual sales after they become operational.

    Business Outlook

    "Following our successful bidding for distribution rights in Guangxi province over the past year, we expect sales under these contracts to become an increasingly larger share of our overall revenues," commented Mr. Tang. "While we continue to pursue an organic growth strategy for our distribution segment, we are also aggressively expanding our retail pharmacy presence throughout Guangxi Province through acquisitions. With the addition of the 48 new stores, we are on track to achieve our target of adding a total of 160 pharmacy stores by the end of 2010 to our growing retail chain in Guangxi Province. We expect to be successful once again in renewing existing and winning new contracts as part of the 2010 centralized tendering under the New Rural Corporative Health Insurance Plan and anticipate significant new business opportunities to drive China BCT's growth."

    About China BCT

    China BCT is engaged in pharmaceutical distribution, pharmacy retailing, and the manufacture of pharmaceuticals products through its subsidiaries Guangxi Liuzhou Baicaotang Medicine Limited, Hefeng Pharmaceutical Co. Limited, and Guangxi Liuzhou Baicaotang Medicine Retail Limited in Guangxi province, China. It operates a large regional retail network in Guangxi province, consisting of 114 directly owned retail stores in Guangxi province and currently over 8,000 products are distributed through the Company's wholesale distribution network.

    Safe Harbor Statement

    This presentation contains "forward-looking statements" within the meaning of the "safe-harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve known and unknown risks, uncertainties and other factors that could cause the actual results of the Company to differ materially from the results expressed or implied by such statements, including the successful integration of newly acquired stores, the achievability of the payback periods, and the revenue generation potential of the newly acquired stores. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company has no obligation to update the forward-looking information contained in this presentation.

    Use of Non-GAAP Financial Information

    GAAP results for the three months ended March 31, 2010 and 2009 include change in fair value of warrant liabilities. To supplement the Company's condensed consolidated financial statements presented on a GAAP basis, the Company has provided non-GAAP financial information excluding the impact of these items in this release, which are non-GAAP net income and non-GAAP diluted earnings per share. The Company's management believes that these non-GAAP measures provide investors with a better understanding of how the results related to the Company's historical performance. The additional adjusted information is not meant to be considered in isolation or as a substitute for GAAP financials. The adjusted financial information that the Company provides also may differ from the adjusted information provided by other companies. Management believes that these adjusted financial measures are useful to investors because they exclude non-cash expenses that management excludes when it internally evaluates the performance of the Company's business and makes operating decisions, including internal budgeting, and performance measurement, as these measures provide a consistent method of comparison to historical periods. As a result, the provision of these adjusted measures allows investors to evaluate the Company's performance using the same methodology and information as that used by the Company's management. Adjusted measures are subject to inherent limitations because they do not include all of the expenses included under GAAP and because they involve the exercise of judgment of which charges are excluded from the adjusted financial measure. However, the Company's management compensates for these limitations by providing the relevant disclosure of the items excluded. A reconciliation of each adjusted measures to the nearest GAAP measure appears in the table below.

    China BCT Pharmacy Group, Inc. RECONCILIATION OF NON-GAAP NET INCOME AND DILUTED EPS Three months Ended March 31, US$ - thousands, except per share 2010 2009 Net income 4,244 5,007 - Non-cash adjustment - Change in fair value of warrant liabilities 289 -- Adjusted net income excluding non-cash item 4,533 5,007 Per diluted share - Net income per share $0.11 $0.16 - Non-cash adjustment per share $0.01 $0.00 - Adjusted net income per share $0.12 $0.16 Weighted average shares outstanding - '000 - diluted 37,765 32,000 Financial Tables Follow China BCT Pharmacy Group, Inc. (Formerly named China Baicaotang Medicine Limited) Condensed Consolidated Statements of Income and Comprehensive Income For the three months ended March 31, 2010 and 2009 (Unaudited) (Stated in US Dollars) Three months ended March 31, 2010 2009 Sales revenue $34,028,878 $32,342,392 Cost of sales 25,167,201 23,493,795 Gross profit 8,861,677 8,848,597 Operating expenses Administrative expenses 1,642,423 996,095 Selling expenses 1,026,519 858,686 2,668,942 1,854,781 Income from operations 6,192,735 6,993,816 Interest income 50,686 106 Other income 98,040 -- Change in fair value of warrant liabilities (288,783) -- Other expenses (39,312) (2,595) Finance costs (263,696) (296,175) Income before income taxes 5,749,670 6,695,152 Income taxes (1,505,505) (1,688,383) Net income attributable to China BCT Pharmacy Group, Inc.'s common stockholders $4,244,165 $5,006,769 Other comprehensive income Foreign currency translation adjustments 24,538 (36,992) Total comprehensive income $4,268,703 $4,969,777 Earnings per share: basic and diluted $0.11 $0.16 Weighted average number of shares outstanding: basic and diluted 37,764,573 32,000,000 China BCT Pharmacy Group, Inc. (Formerly named China Baicaotang Medicine Limited) Condensed Consolidated Balance Sheets As of March 31, 2010 and December 31, 2009 (Stated in US Dollars) March 31, December 31, 2010 2009 (Unaudited) (Audited) ASSETS Current assets Cash and cash equivalents $13,033,360 $13,304,158 Restricted cash 871,714 1,155,779 Bills receivable 129,956 -- Trade receivables, net 35,110,436 35,410,039 Amounts due from related companies 7,896,323 4,275,586 Other receivables, prepayments and deposits 4,055,276 2,526,398 Inventories 10,761,047 8,745,525 Deferred taxes 28,932 60,164 Total current assets 71,887,044 65,477,649 Goodwill 107,968 107,968 Other intangible assets 625,520 660,034 Property, plant and equipment, net 12,028,584 12,171,689 Land use rights 13,218,822 13,979,753 Deposit for acquisition of retail chain stores business 2,434,101 -- Deferred taxes 696,149 663,699 TOTAL ASSETS $100,998,188 $93,060,792 China BCT Pharmacy Group, Inc. (Formerly named China Baicaotang Medicine Limited) Condensed Consolidated Balance Sheets (Cont'd) As of March 31, 2010 and December 31, 2009 (Stated in US Dollars) March 31, December 31, 2010 2009 (Unaudited) (Audited) LIABILITIES AND STOCKHOLDERS' EQUITY LIABILITIES Current liabilities Trade payables $20,744,178 $19,159,212 Bills payable 1,743,428 2,239,604 Other payables and accrued expenses 3,786,462 3,194,612 Amounts due to directors 848,208 1,008,111 Amounts due to related companies 922,913 128,579 Income tax payable 682,251 562,603 Secured bank loans 6,626,811 7,136,069 Other loans 1,500,569 2,361,258 Retirement benefit costs 59,158 59,158 Total current liabilities 36,913,978 35,849,206 Secured long-term bank loans 3,631,957 3,631,957 Warrant liabilities 2,144,202 -- Retirement benefit costs 201,320 201,320 TOTAL LIABILITIES 42,891,457 39,682,483 COMMITMENTS AND CONTINGENCIES STOCKHOLDERS' EQUITY Common stock: par value $0.001 per share Authorized 100,000,000 shares and 38,119,340 and 37,089,370 shares issued and outstanding as of March 31, 2010 and December 31, 2009 respectively 38,119 37,089 Additional paid-in capital 15,379,588 14,920,899 Statutory and other reserves 2,605,901 2,605,901 Accumulated other comprehensive income 2,134,808 2,110,270 Retained earnings 37,948,315 33,704,150 TOTAL STOCKHOLDERS' EQUITY 58,106,731 53,378,309 TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $100,998,188 $93,060,792 China BCT Pharmacy Group, Inc. (Formerly named China Baicaotang Medicine Limited) Condensed Consolidated Statements of Cash Flows For the three months ended March 31, 2010 and 2009 (Unaudited) (Stated in US Dollars) Three months ended March 31, 2010 2009 Cash flows from operating activities Net income attributable to China BCT Pharmacy Group, Inc.'s common stockholders $4,244,165 $5,006,769 Adjustments to reconcile net income to net cash provided by (used in) operating activities:- Depreciation 181,481 158,941 Deferred taxes (1,218) -- Gain on disposal of land use right (44,919) -- Loss on disposal of property, plant and equipment -- 306 Amortization of intangible assets 34,514 29,024 Amortization of land use rights 108,355 83,873 Change in fair value of warrant liabilities 288,783 -- Changes in operating assets and liabilities:- Trade receivables 299,603 (7,574,526) Bills receivable (129,956) -- Other receivables, prepayments and deposits (1,528,878) (1,477,625) Inventories (2,015,522) (440,823) Trade payables 1,584,966 (1,397,972) Amounts due from (to) related companies 388,390 (277,722) Other payables and accrued expenses 591,850 1,463,456 Bills payable (496,176) 2,223,521 Restricted cash 284,065 (2,201,559) Income tax payable 119,648 344,597 Net cash flows provided by (used in) operating activities $3,909,151 $(4,059,740) China BCT Pharmacy Group, Inc. (Formerly named China Baicaotang Medicine Limited) Condensed Consolidated Statements of Cash Flows (Cont'd) For the three months ended March 31, 2010 and 2009 (Unaudited) (Stated in US Dollars) Three months ended March 31, 2010 2009 Cash flows from investing activities Payments to acquire and deposit for acquisition of property, plant and equipment $(38,376) $(14,110) Proceeds from sales of property, plant and equipment -- 407 Proceeds from sales of land use right 697,495 -- Deposit for acquisition of retail chain stores business (2,434,101) -- Repayment from related companies -- 3,671,755 Net cash flows (used in) provided by investing activities (1,774,982) 3,658,052 Cash flows from financing activities Repayment (to) from related companies (3,214,793) 1,040,480 Repayment to directors (159,903) -- Net cash received from private placement 2,315,138 -- Proceeds from bank loans 1,290,960 9,675,520 Repayment of bank loans (1,800,218) (7,243,454) Repayment of other loans (860,689) (122,333) Net cash flows (used in) provided by financing activities (2,429,505) 3,350,213 Effect of foreign currency translation on cash and cash equivalents 24,538 (2,571) Net (decrease) increase in cash and cash equivalents (270,798) 2,945,954 Cash and cash equivalents - beginning of period 13,304,158 1,265,184 Cash and cash equivalents - end of period $13,033,360 $4,211,138 Supplemental disclosures for cash flow information: Cash paid for: Interest $196,262 $218,520 Income taxes $1,387,075 $1,343,750 For more information, please contact: Company Contact: Ms. Shelly Zhang, Chief Financial Officer China BCT Pharmacy Group, Inc. Email: z_shelly@hotmail.com Tel: +86-772-363-8318 Investor Relations Contact: Ms. Lei Huang, Account Manager Email: lei.huang@ccgir.com Tel: +1-646-833-3417 Mr. Crocker Coulson, President Email: crocker.coulson@ccgir.com Tel: +1-646-213-1915 CCG Investor Relations Web: http://www.ccgirasia.com/

    China BCT Pharmacy Group, Inc.

    CONTACT: Shelly Zhang, Chief Financial Officer of China BCT Pharmacy
    Group, Inc., +86-772-363-8318, z_shelly@hotmail.com; or Investors, Ms. Lei
    Huang, Account Manager, +1-646-833-3417, lei.huang@ccgir.com, or Crocker
    Coulson, President, +1-646-213-1915, crocker.coulson@ccgir.com, CCG Investor
    Relations




    American Woodmark Corporation Announces Cash Dividend

    WINCHESTER, Va., May 21 /PRNewswire-FirstCall/ -- American Woodmark Corporation today announced a quarterly cash dividend of $0.09 per share to be paid on June 18, 2010, to shareholders of record on June 4, 2010.

    American Woodmark Corporation, located in Winchester, Virginia, is the third largest manufacturer of kitchen and bath cabinets in the United States. Offering approximately 400 cabinet lines in a wide variety of designs, materials and finishes, American Woodmark products are sold through a network of dealers and distributors and directly to home centers and major home builders.

    The Company currently operates 11 manufacturing facilities in Arizona, Georgia, Indiana, Kentucky, Maryland, Tennessee, Virginia and West Virginia, as well as various service centers across the country. To find out more about American Woodmark, and view its vast array of cabinet styles, visit its web site at http://www.americanwoodmark.com/.

    AMWD-F

    AMWD-G

    American Woodmark Corporation

    CONTACT: Glenn Eanes, Vice President and Treasurer, +1-540-665-9100

    Web Site: http://www.americanwoodmark.com/




    AT&T Unveils New Wireless Store in SalemStore Offers Hands-On, Interactive Retail Experience for Customers in New Hampshire

    SALEM, N.H., May 21 /PRNewswire-FirstCall/ -- As people's lives become increasingly mobile and fast-paced, and to address the growing demand for advanced wireless data products and services, AT&T* today announced the opening of a new wireless retail store in Salem.

    The store, located in the Rockingham Mall in Salem, has a state-of-the-art, hands-on design to engage customers and provide a "try before buy" service experience. Trained sales consultants will provide demonstrations of a wide range of wireless products and services. Shoppers can also test out various advanced wireless data applications including GPS navigation, mobile social networking or mobile television.

    The Rockingham Mall store is led by Lloyd Fernandes and has a staff of ten employees who are trained to assist customers -- both business and consumer -- with purchasing decisions, customer service and technical support. Hours of operation are Monday through Saturday 10:00 a.m. - 9:00 p.m., Sunday 12:00 p.m. - 6:00 p.m.

    The store, which officially opens today, will celebrate with a ribbon cutting on Thursday, May 27th at 9 a.m.

    AT&T operates nine AT&T-owned retail locations in New Hampshire. Its products and services are also available at a number of other authorized dealers and national retail locations.

    To find out more details about AT&T's coverage in New Hampshire or anywhere in the United States, consumers can go to http://www.wireless.att.com/coverageviewer/. The online tool provides up-to-date wireless coverage information for specific locations. The tool can measure the quality of coverage based on a street address, intersection, ZIP code or even a landmark.

    *AT&T products and services are provided or offered by subsidiaries and affiliates of AT&T Inc. under the AT&T brand and not by AT&T Inc. The Samsung Strive(TM) is just $19.99 with minimum $20/mo data package purchase and a wireless voice plan with a new two-year agreement.

    About AT&T

    AT&T Inc. is a premier communications holding company. Its subsidiaries and affiliates - AT&T operating companies - are the providers of AT&T services in the United States and around the world. With a powerful array of network resources that includes the nation's fastest 3G network, AT&T is a leading provider of wireless, Wi-Fi, high speed Internet and voice services. A leader in mobile broadband, AT&T also offers the best wireless coverage worldwide, offering the most wireless phones that work in the most countries. It also offers advanced TV services under the AT&T U-verse® and AT&T | DIRECTV(SM) brands. The company's suite of IP-based business communications services is one of the most advanced in the world. In domestic markets, AT&T Advertising Solutions and AT&T Interactive are known for their leadership in local search and advertising. In 2010, AT&T again ranked among the 50 Most Admired Companies by FORTUNE® magazine.

    Additional information about AT&T Inc. and the products and services provided by AT&T subsidiaries and affiliates is available at http://www.att.com/. This AT&T news release and other announcements are available at http://www.att.com/newsroom and as part of an RSS feed at http://www.att.com/rss. Or follow our news on Twitter at @ATTNews. Find us on Facebook at http://www.facebook.com/ATT to discover more about our consumer and wireless services or at http://www.facebook.com/ATTSmallBiz to discover more about our small business services.

    Cautionary Language Concerning Forward-Looking Statements

    Information set forth in this press release contains financial estimates and other forward-looking statements that are subject to risks and uncertainties, and actual results might differ materially. A discussion of factors that may affect future results is contained in AT&T's filings with the Securities and Exchange Commission. AT&T disclaims any obligation to update and revise statements contained in this news release based on new information or otherwise.

    © 2010 AT&T Intellectual Property. All rights reserved. 3G service not available in all areas. AT&T, the AT&T logo and all other marks contained herein are trademarks of AT&T Intellectual Property and/or AT&T affiliated companies.

    AT&T Inc.

    CONTACT: Kate MacKinnon of AT&T Inc., +1-508-271-8442,
    kate.mackinnon@att.com

    Web Site: http://www.att.com/




    Oberthur Technologies and Smart Association Team up to Provide Smart Card-Centric ID Solution to Patients in New York

    CHANTILLY, Virginia, May 21, 2010 /PRNewswire-FirstCall/ -- Oberthur Technologies, a global leader in the delivery of high security solutions and the #1 provider of smart credentials to the U.S. Federal government, has teamed up with one of healthcare's leading smart card software providers, SMART Association Inc., to offer a powerful, proven and secure, physical and logical access smart card-based admissions solution to hospitals and clinics throughout North America. The first of these solutions assists patients at Wyckoff Heights Medical Center.

    The Brooklyn NY.-based, 305 bed teaching hospital, which offers emergency care as well as outpatient services to more than 75,000 visitors annually, needed a way to speed up patient registration and assist in providing accurate, updated admissions information. "We are constantly looking for ways to make the patient experience a positive one," said Rajiv Garg Wyckoff's President and Chief Executive Officer. "Offering an easier way to see their doctor is just the tip of the iceberg- being able to quickly verify the patient's identity and provide error-proof registration in seconds is the real benefit."

    Oberthur Technologies will provide Wyckoff enrollment work stations and its Personal Identification Verification (PIV)-based, ID-One(TM) Cosmo smart card, the same card used by millions of Americans to secure their personal identifiable information. "We're providing Wyckoff a proven, interoperable, non proprietary platform on which to build a patient centric, Health-IT infrastructure," said Patrick W. Hearn, Oberthur's VP of Government and Identification Markets - America's. "Teaming up with Smart Association allows Oberthur to offer an end-to-end solution that utilizes our standards-driven tools with an intuitive patient admissions software program. It will now allow Health care institutions to provide the proper level of authentication to protect patient privacy."

    SMART Association's patient admissions and identity software, LifeMed(TM), will allow Wyckoff admissions staff to securely identify and authenticate the patient and the data on the card. "LifeMed streamlines the patient admissions process and connects the patient's smart card instantly to external data sources such as clinicians EMRs, HIEs, etc., creating a comprehensive medical record, providing a more accurate and up-to-date patient record," said David Batchelor, CEO of Smart Association. "By utilizing LifeMed software with Oberthur Technologies, our clients increase administrative efficiencies and patient satisfaction by allowing them to carry and securely transmit their personal medical information on a proven smart card. In addition, organizations that have used LifeMed have seen a return on investment within 8-16 months of installation by reducing duplicate records, record errors, medical fraud, admissions paper and other administrative costs."

    Cards will start being issued to Wyckoff patients second quarter of 2010. About Smart Association

    For over 19 years, Smart Association has been leading provider of Consumer Relationship Marketing services, and is now a leading software provider for patient smart card solutions within healthcare. The Company's LifeMed(TM) Patient Smart Card Platform uses smart cards, plug and play readers and kiosks to streamline patient admissions, connect previously unconnected providers' medical information systems creating a "best medical record," and makes the entire non-medical aspect of patient healthcare delivery a less burdensome process. One card identity and multiple touch point solutions. Learn more at http://www.smartassociation.com/

    About Oberthur Technologies

    With sales of 905 million Euros in 2009, Oberthur Technologies is a world leader in the field of secure technologies. Innovation and excellence ensure Oberthur Technologies' strong positioning in its main target markets:

    - Card Systems: The world's second largest provider of security and identification based on smart card technology and associated services for mobile, payment, transport, digital TV and convergence markets. - Identity: Leading international supplier for the manufacture and personalization of secure identity documents such as passport, identity card, driving license or health care card - traditional and electronic - and associated services for both governmental and corporate markets. - Security printing: A key player in the secure printing industry specialized in the production of banknotes, checks and other security documents in more than fifty countries. - Cash protection: World leader in the emerging market of intelligent systems to secure cash-in-transit and ATM.

    Close to its customers, Oberthur Technologies benefits from an industrial and commercial presence across all five continents.

    Oberthur Technologies S.A. is a limited liability company (societe anonyme) registered in France with its registered office at 50 quai Michelet 92 532 Levallois Perret, France. Oberthur Technologies S.A.'s corporate registration number is 340 709 534 R.C.S. Paris.

    Website: http://www.oberthur.com/

    Oberthur Technologies

    CONTACT: U.S. Press Contact: Leana Benson Hersch, Phone:
    +1-310-868-1318, Email: l.hersch@oberthur.com; Corporate Press Contact: Sara
    Depagneux, Phone: +33-1-55-46-72-00, Email: s.depagneux@oberthur.com




    Micromet to Provide Update on BiTE Antibody Development Programs at Upcoming Medical Conferences- Updated Results from ALL and NHL Trials of Blinatumomab Accepted for Oral Presentations at EHA -

    BETHESDA, Md., May 21 /PRNewswire-FirstCall/ -- Micromet, Inc. , a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced that updates on several of its BiTE antibody development programs will be made at two upcoming medical conferences.

    Blinatumomab (MT103), the Company's lead product candidate, will be the subject of two oral presentations at the 15th Annual Congress of the European Hematology Association, to be held June 10 - 13 in Barcelona.

    In a presentation titled Prolonged Leukemia Free Survival Following Blinatumomab Treatment of Patients with Minimal Residual Disease of B Precursor ALL: Updated Results of a Phase 2 Study (abstract # 1700), Professor Ralf Bargou, Division of Hematology and Oncology, Department of Internal Medicine II, Wurzburg University Hospital, will report updated data from a Phase 2 trial of blinatumomab in patients with MRD-positive acute lymphoblastic leukemia (ALL). Dr. Bargou, the study's principal investigator, will present updated duration of response data on 19 evaluable patients on June 12 from 4:30 - 4:45 PM CET. Earlier results from this trial provided the basis for a pivotal trial that the Company plans to initiate in the third quarter of this year.

    In a presentation titled CD3/CD19 bispecific BiTE® Antibody Blinatumomab Treatment of Non-Hodgkin Lymphoma (NHL) Patients: 60 micrograms/square meter/d by Continuous Infusion is Tolerable and Results in Durable Responses, (abstract # 433), Mariele Goebeler, Wurzburg University Hospital, will report updated results from an on-going Phase 1 trial of blinatumomab in patients with relapsed or refractory non-Hodgkin's lymphoma (NHL). Dr. Goebeler will present an update on the experience of patients treated with blinatumomab utilizing a new dosing algorithm on June 12 from 9:00 - 9:15 AM CET.

    At the 2010 American Society of Clinical Oncology Annual Meeting, to be held June 4 - 8 in Chicago, Walter Fiedler, Department of Medicine II, University Hospital Hamburg-Eppendorf will report updated results from an ongoing Phase 1 trial of MT110 in patients with advanced solid tumors. In a poster presentation titled Phase I Safety and Pharmacology Study of the EpCAM/CD3-bispecific BiTE® Antibody MT110 in Patients with Metastatic Colorectal, Gastric or Lung Cancer (abstract # 2573), Dr. Fiedler will present interim findings from this dose escalation study on June 7 from 8:00 AM - 12:00 PM CST.

    Abstracts can be found at http://www.ehaweb.org/ and http://www.asco.org/. About Blinatumomab

    Blinatumomab (MT103) is a novel, next-generation monoclonal antibody designed to direct the body's cell destroying T-cells against CD19, a protein expressed on the surface of most B-cell derived non Hodgkin's lymphomas. Blinatumomab has demonstrated potent activity against adult Acute Lymphocytic Leukemia, achieving an 80% molecular response rate in a Phase 2 study. Blinatumomab was generally well-tolerated by patients in the Phase 2 study. The most frequently reported grade 3/4 adverse event was lymphopenia. All other adverse events were infrequent and transient in nature. Micromet received orphan drug designation from the EMEA for blinatumomab for the treatment of ALL in August 2009.

    About Micromet, Inc.

    Micromet, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibody-based therapies for the treatment of cancer. Its product development pipeline includes novel antibodies generated with its proprietary BiTE® technology, as well as conventional monoclonal antibodies. Two of Micromet's BiTE antibodies and three of its conventional antibodies are currently in clinical trials. Micromet has collaborations with a number of leading pharmaceutical and biotechnology companies, including sanofi-aventis, Bayer Schering Pharma, Merck Serono, Boehringer Ingelheim, MedImmune and Nycomed. Additional information can be found at http://www.micromet-inc.com/.

    Micromet, Inc.

    CONTACT: Jennifer Neiman, Director, Corporate Communications of
    Micromet, Inc., +1-240-235-0246, jennifer.neiman@micromet-inc.com

    Web Site: http://www.micromet-inc.com/




    Ann Taylor Reports Strong First Quarter Earnings Per Share of $0.38-- Results Driven by Double Digit Comparable Sales Increase at Both Brands and a Gross Margin Rate of 59.4% --

    NEW YORK, May 21 /PRNewswire-FirstCall/ -- Ann Taylor Stores Corporation today reported results for the fiscal first quarter ended May 1, 2010, and commented on its outlook for the second quarter and fiscal year 2010.

    For the first quarter of 2010, the Company reported earnings per diluted share of $0.38 on both a GAAP and operating basis. This compares with a first quarter 2009 loss per diluted share of $0.04 on a GAAP basis, and a first quarter 2009 operating loss per diluted share of $0.03, excluding an after-tax restructuring charge of $0.01 per share.

    Kay Krill, President and Chief Executive Officer, commented, "Fiscal 2010 is off to an excellent start, with both Ann Taylor and LOFT achieving outstanding results for the first quarter. A substantial uptick in sales, including double-digit comparable sales increases at both brands, and a strong gross margin rate drove the dramatic improvement over year-ago results. Clients responded positively to our Spring collections at both brands, and we were pleased with the increased traffic levels and improved in-store metrics during the quarter.

    "We will continue to position both brands to deliver profitable sales growth in 2010. At the same time, we will remain focused on delivering strong gross margin while managing our inventory levels to support expected top-line growth. We are excited about our first quarter results at both brands and look forward to building on our progress for the balance of the year," said Ms. Krill.

    Fiscal 2010 First Quarter Results

    Ms. Krill continued, "Beginning this quarter, we are providing enhanced transparency on our sales results by brand and channel. This approach best reflects how we and, frankly our clients, view our business - as two brands, each with three channels - a view that we believe will strengthen over time as we create a more seamless multi-channel brand experience for our clients."

    Total net sales for the first quarter of fiscal 2010 were $476.2 million, compared with net sales of $426.7 million in the first quarter of fiscal 2009. By brand, net sales across all channels of the Ann Taylor brand totaled $198.4 million in the first quarter of 2010, compared with net sales of $178.3 million in the first quarter of 2009. At the LOFT brand, net sales across all channels were $277.8 million in the first quarter of 2010, compared with net sales of $248.5 million in the first quarter of 2009.

    Total Company comparable sales for the quarter increased 14.1%, versus a decline of 30.2% in the prior year. At Ann Taylor, total brand comparable sales increased 16.4%, including increases of 15.1% at Ann Taylor stores, 50.7% in the Ann Taylor e-commerce channel and 10.7% in the Ann Taylor Factory channel. At LOFT, total brand comparable sales increased 12.5%, including increases of 9.3% at LOFT stores, 59.9% in the LOFT e-commerce channel and 24.1% in the LOFT Outlet channel. (Please refer to Table 3 for a breakdown of sales by brand and channel.)

    Gross margin, as a percentage of net sales, was 59.4%, reflecting a 390 basis point improvement over the 55.5% gross margin rate achieved in the first quarter of 2009. The strong gross margin performance was primarily driven by improved product offerings at both brands, higher full-price selling, effective marketing initiatives and the success of the Company's strategy to appropriately position inventory levels.

    Selling, general and administrative expenses for the first quarter of 2010 were $243.8 million, reflecting incremental marketing investment, an increase in variable costs related to higher sales as well as an increase in performance-based compensation expense versus the 2009 period, partially offset by restructuring program savings.

    During the quarter, the Company recorded pre-tax restructuring charges of $0.4 million associated with its previously announced strategic restructuring program, compared with $1.0 million in the first quarter of 2009. On an after-tax basis, first quarter 2010 restructuring charges totaled $0.2 million, or $0.00 per diluted share, compared with $0.7 million, or $0.01 per diluted share, in the first quarter of 2009.

    Excluding the aforementioned charges, the Company reported operating income of $39.1 million for the quarter, compared with an operating loss of $1.8 million in the first quarter of 2009. On the same basis, the Company reported net income in the quarter of $22.8 million, or $0.38 per diluted share, compared with a net loss of $1.6 million, or $0.03 per diluted share, in the first quarter of 2009.

    On a GAAP basis, the Company reported operating income of $38.7 million in the first quarter of 2010, compared with an operating loss of $2.7 million in the first quarter of 2009. On the same basis, the Company reported net income of $22.6 million, or $0.38 per diluted share, in the first quarter of 2010, compared with a net loss of $2.3 million, or $0.04 per diluted share, in the first quarter of 2009.

    The Company closed the quarter with approximately $207 million in cash and cash equivalents.

    Total inventory per square foot at the end of the first quarter was down 2.3% versus year-ago, reflecting an 11.5% increase at Ann Taylor stores, offset by a 3.1% decline at LOFT stores as well as inventory declines in our factory/outlet channels.

    During the first quarter of 2010, the Ann Taylor brand closed three Ann Taylor stores and converted five Ann Taylor stores to LOFT stores. At the LOFT brand, the Company closed one LOFT store. The Company did not open any new stores during the quarter. The total store count at the end of the first quarter was 903, comprised of 283 Ann Taylor stores, 92 Ann Taylor Factory stores, 510 LOFT stores, and 18 LOFT Outlet stores. The Company updated expectations related to the store closure component of its previously announced strategic restructuring program. Under the program, the Company now expects to close approximately 61 stores in fiscal 2010, bringing the total for the three-year program to approximately 163 store closures. Of these, approximately half are expected to be Ann Taylor stores and half are expected to be LOFT stores.

    Outlook for Fiscal Second-Quarter and Full-Year 2010 Update

    For the fiscal second quarter of 2010, the Company expects total net sales to approach $500 million, reflecting double-digit comparable sales performance. Gross margin rate performance is expected to be approximately 250 basis points better than the 52.4% rate achieved in the second quarter of 2009. Selling, general and administrative expenses are estimated to be approximately $245 million, including approximately $5 million in incremental marketing investment to drive ongoing sales momentum, compared with the second quarter of 2009.

    In terms of the full year, the Company updated its outlook as follows: -- The Company currently expects fiscal 2010 total net sales in the range of $1.950 to $1.975 billion. In addition, the Company anticipates positive comparable sales at both brands and all channels in each of the fiscal quarters of 2010, as a result of more compelling product assortments, strategic marketing initiatives and a disciplined approach to inventory management. -- Gross margin rate performance is expected to be approximately 150 basis points better than the 54.4% rate achieved in fiscal 2009. -- Selling, general and administrative expenses are expected to be approximately $985 million, reflecting the ongoing benefits of the Company's strategic restructuring program offset primarily by an increase in variable costs related to higher sales, an incremental investment in marketing and operating costs associated with the 30 new stores planned for fiscal 2010. -- A full-year 2010 effective tax rate of approximately 40%. -- Incremental restructuring savings for the year are expected to total approximately $20 million and one-time restructuring costs are estimated to be in the range of $2 to $12 million. -- Total weighted average square footage is expected to decline approximately 3% by year-end, reflecting the impact of approximately 61 store closures in fiscal 2010 under the Company's previously announced restructuring program, partially offset by the opening of approximately 30 new stores to support the continued growth of the LOFT brand. -- Capital expenditures are expected to be approximately $70 million. -- A continued focus on maintaining a healthy balance sheet is expected to result in a year-end cash position that will exceed the Company's cash position at year-end 2009, and the Company expects to maintain a disciplined approach to inventory management throughout the fiscal year. FORWARD-LOOKING STATEMENTS

    Certain statements in this press release are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements may use the words "expect", "anticipate", "plan", "intend", "project", "may", "believe" and similar expressions. Forward-looking statements also include representations of the expectations or beliefs of the Company concerning future events that involve risks and uncertainties, including:

    -- effectiveness of the Company's brand awareness and marketing programs, and its ability to maintain the value of its brands; -- the Company's ability to accurately predict client fashion preferences and trends and provide merchandise that satisfies client demands in a timely manner; -- the Company's ability to successfully execute brand extensions and new concepts; -- competitive influences and decline in the demand for merchandise offered by the Company, and the Company's ability to manage inventory levels and merchandise mix; -- the Company's ability to hire, retain and train key personnel; -- the Company's ability to optimize its store portfolio and effectively manage the profitability of its existing stores; -- the Company's reliance on independent foreign sources of production, including financial or political instability, supplier inability to obtain adequate access to liquidity to finance their operations, the imposition of duties or other possible trade law or import restrictions, including legislation relating to import quotas, as well as increases in the costs of raw materials and freight; -- the Company's ability to successfully upgrade and maintain its information systems, including adequate system security controls; -- the Company's ability to continue operations in accordance with its business continuity plan in the event of an interruption; -- the Company's dependence on a single distribution facility and third-party transportation companies; -- the performance and operations of the Company's websites; -- general economic conditions and the recent financial crisis, including the resultant downturn in the retail industry, and their effects on the Company's liquidity and capital resources; -- continuation of lowered levels of consumer spending and consumer confidence, changes in levels of store traffic and higher levels of unemployment resulting from the worldwide economic downturn; -- fluctuation in the Company's level of sales and earnings growth and stock price; -- a significant change in the regulatory environment applicable to the Company's business and the Company's ability to comply with legal and regulatory requirements; -- continued volatility and deterioration of the financial markets, including further tightening of the credit environment, fluctuations in interest rates and exchange rates or restrictions on the transfer of funds; -- the Company's ability to secure and protect trademarks and other intellectual property rights; -- failure by independent manufacturers to comply with the Company's quality, product safety and social practices requirements; -- the inability of the Company, particularly through its sourcing and logistics functions, to operate within production and delivery constraints; -- acts of war or terrorism in the United States or worldwide; -- the potential impact of natural disasters and public health concerns, including severe infectious diseases, particularly on the Company's foreign sourcing offices and manufacturing operations of the Company's vendors; -- work stoppages, slowdowns or strikes; -- the Company's ability to achieve the results of its restructuring program, including changes in management's assumptions and projections concerning costs and timing; -- the Company's ability to realize deferred tax assets; -- the effect of external economic factors on the Company's future funding obligations for its defined benefit pension plan; and -- the bankruptcy or significant deterioration of the Company's major national landlords.

    Further description of these risks and uncertainties and other important factors are set forth in the Company's latest Annual Report on Form 10-K, including but not limited to Item 1A - Risk Factors and Item 7 - Management's Discussion and Analysis of Financial Condition and Results of Operations therein, and in the Company's other filings with the SEC. Although these forward-looking statements reflect the Company's current expectations concerning future events, actual results may differ materially from current expectations or historical results. The Company does not assume any obligation to publicly update or revise any forward-looking statements at any time for any reason.

    About Ann Taylor

    Ann Taylor Stores Corporation is one of the leading women's specialty retailers for fashionable clothing in the United States, operating 903 Ann Taylor, Ann Taylor Factory, LOFT and LOFT Outlet stores in 46 states, the District of Columbia and Puerto Rico as of May 1, 2010, as well as online at AnnTaylor.com and LOFTonline.com. Visit AnnTaylorStoresCorp.com for more information .

    ANNTAYLOR STORES CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS For the Quarters Ended May 1, 2010 and May 2, 2009 (unaudited) Table 1. Quarters Ended -------------- May 1, 2010 May 2, 2009 ----------- ----------- (in thousands, except per share amounts) Net sales $476,181 $426,747 Cost of sales 193,290 189,889 ------- ------- Gross margin 282,891 236,858 Selling, general and administrative expenses 243,799 238,611 Restructuring charges 385 964 --- --- Operating income/(loss). 38,707 (2,717) Interest income 226 273 Interest expense. 405 779 --- --- Income/(loss) before income taxes 38,528 (3,223) Income tax provision/(benefit) 15,912 (909) ------ ---- Net income/(loss) $22,616 $(2,314) ======= ======= Earnings per share: ------------------- Basic earnings/(loss) per share. $0.38 $(0.04) Weighted average shares outstanding 57,406 56,550 Diluted earnings/(loss) per share $0.38 $(0.04) Weighted average shares outstanding, assuming dilution 58,393 56,550 ANNTAYLOR STORES CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS May 1, 2010, January 30, 2010 and May 2, 2009 (unaudited) Table 2. January May 1, 30, May 2, 2010 2010 2009 ---- ---- ---- Assets (in thousands) Current assets Cash and cash equivalents $207,129 $204,491 $198,695 Short-term investments 5,704 5,655 - Accounts receivable 31,582 19,267 31,051 Merchandise inventories 199,620 169,141 212,276 Refundable income taxes 24,443 24,929 1,602 Deferred income taxes 32,281 35,799 21,322 Prepaid expenses and other current assets 43,539 45,613 57,969 ------ ------ ------ Total current assets 544,298 504,895 522,915 Property and equipment, net 348,055 365,934 460,249 Deferred financing costs, net 897 973 1,199 Deferred income taxes 32,071 23,683 50,590 Other assets 7,145 6,656 12,986 ----- ----- ------ Total assets $932,466 $902,141 $1,047,939 ======== ======== ========== Liabilities and Stockholders' Equity Current liabilities Accounts payable $90,208 $76,969 $91,138 Credit facility - - 125,000 Accrued salaries and bonus. 18,144 32,168 20,319 Accrued tenancy 43,608 44,878 41,625 Gift certificates and merchandise credits redeemable 39,455 47,555 38,563 Accrued expenses and other current liabilities 87,291 73,804 82,729 ------ ------ ------ Total current liabilities 278,706 275,374 399,374 Deferred lease costs 175,754 183,917 210,890 Deferred income taxes 1,119 1,584 1,769 Other liabilities 32,650 24,080 17,906 Commitments and contingencies Stockholders' equity Common stock, $.0068 par value; 200,000,000 shares authorized; 82,489,828, 82,476,328 and 82,476,328 shares issued, respectively 561 561 561 Additional paid-in capital 782,119 777,786 765,367 Retained earnings 436,910 414,294 430,188 Accumulated other comprehensive loss (4,078) (4,158) (7,506) ------ ------ ------ 1,215,512 1,188,483 1,188,610 --------- --------- --------- Treasury stock, 23,698,496, 23,701,800 and 23,916,352 shares respectively, at cost (771,275) (771,297) (770,610) -------- -------- -------- Total stockholders' equity 444,237 417,186 418,000 ------- ------- ------- Total liabilities and stockholders' equity $932,466 $902,141 $1,047,939 ======== ======== ========== ANNTAYLOR STORES CORPORATION Brand Sales and Store Data For the Quarters Ended May 1, 2010 and May 2, 2009 (unaudited) Table 3. Quarters Ended -------------- Sales and Comps May 1, 2010 May 2, 2009 Sales Comp (1) Sales Comp (1) ----- -------- ----- -------- ($ in thousands) Ann Taylor Ann Taylor Stores $115,265 (1) 15.1% $108,171 (1) (42.7) % Ann Taylor e- commerce 20,871 50.7% 14,138 (27.0) % ------ ------ Subtotal 136,136 19.3% 122,309 (41.3) % Ann Taylor Factory 62,227 (1) 10.7% 55,983 (1) (25.0) % ------ ------ Total Ann Taylor Brand $198,363 16.4% $178,292 (37.6) % ======== ======== LOFT LOFT Stores $243,077 (1) 9.3% $224,320 (1) (24.2) % LOFT e- commerce 21,515 59.9% 13,714 (14.7) % ------ ------ Subtotal 264,592 12.1% 238,034 (23.7) % LOFT Outlet 13,226 (1) 24.1% 10,421 (1) N/A ------ ------ Total LOFT % Brand $277,818 12.5% $248,455 (23.7 ) ======== ======== Total (30.2 ) Company $476,181 14.1% $426,747 % ======== ======== Quarters Ended -------------- Stores And Square Feet May 1, 2010 May 2, 2009 Square Square Stores Feet Stores Feet ------ ------- ------ ------- (square feet in thousands) Ann Taylor Ann Taylor Stores 283 1,537 318 1,714 Ann Taylor Factory 92 668 91 662 --- --- --- --- Total Ann Taylor Brand 375 2,205 409 2,376 === ===== === ===== LOFT LOFT Stores 510 2,996 513 3,023 LOFT Outlet 18 123 17 116 --- --- --- --- Total LOFT Brand 528 3,119 530 3,139 === ===== === ===== Total Company 903 5,324 939 5,515 === ===== === ===== Number Of: Stores open at beginning of period 907 5,348 935 5,492 New stores - - 9 52 Expanded/ downsized stores (2) - (4) - - Closed stores (4) (20) (5) (29) --- --- --- --- Stores open at end of period 903 5,324 939 5,515 === ===== === ===== Converted stores (3) 5 - - - (1) A store is included in comparable sales in its thirteenth month of operation. A store with a square footage change of more than 15% is treated as a new store for the first year following its reopening. (2) The number of stores that were expanded or downsized during the quarters ended May 1, 2010 and May 2, 2009 were 2 and 1, respectively. (3) During the quarter ended May 1, 2010, five Ann Taylor stores were converted to LOFT stores.

    Ann Taylor Stores Corporation

    CONTACT: Investor Contact: Judith Pirro, Vice President, Investor
    Relations, +1-212-541-3300 ext. 3598, Press Contact: Catherine Fisher, Vice
    President, Corporate Communications, +1-212-541-3300 ext. 2199, both of Ann
    Taylor Stores Corporation

    Web Site: http://www.anntaylor.com/




    YM BioSciences announces presentations on global nimotuzumab trials at ASCO annual meeting

    MISSISSAUGA, May 21 /PRNewswire-FirstCall/ -- YM BioSciences Inc. (NYSE Amex:YMI, TSX:YM), today announced that three poster presentations and a published abstract will report results from several global nimotuzumab trials in adults with Glioblastoma Multiforma and in patients with head and neck cancer at the American Society of Clinical Oncology annual meeting held from June 4-8, 2010 in Chicago, Illinois. The trials are being conducted by Oncoscience AG (Wedel, Germany), YM's licensee for nimotuzumab in Europe, and Biocon Limited (Bangalore, India), a licensee of CIMAB SA, YM's licensor.

    Glioblastoma Multiforma

    The poster entitled "Current status of phase III anti-EGF-receptor antibody (OSAG-101) for newly diagnosed glioblastoma (abstract # 2056)" will be presented in the Central Nervous System Tumors general poster session on Sunday June 6th from 8:00AM until 12:00PM in S Hall A2. The trial completed enrollment during the beginning of 2010 and preliminary study results will be presented at the meeting.

    The abstract entitled "Feasibility and safety of combining nimotuzumab with temozolomide and radiotherapy in adult patients with glioblastoma: An Indian clinical experience (abstract # e12509)" will be published in conjunction with the ASCO annual meeting. Preliminary results from this study suggest that the combination of nimotuzumab with temozolomide and radiotherapy is safe and can lead to improved survival outcomes.

    Head and neck cancer

    The poster entitled "An open-label, randomized, study of h-R3mAb (nimotuzumab) in patients with advanced (stage III or IVa) squamous cell carcinoma of head and neck (SCCHN): Four-year survival results from a phase IIb study (abstract # 5530)" will be presented in the Head and Neck Cancer general poster session on Friday June 4th from 2:00PM until 6:00PM in S403, with discussion from 5:00PM until 6:00PM in S406, the Vista Room. This randomized trial demonstrates that the benefit of adding nimotuzumab to radiation and chemoradiation is durable and persists for several years.

    The poster entitled "Results from a pilot study of nimotuzumab with concurrent chemoradiation in patients with locally advanced squamous cell carcinoma of head and neck (abstract # 5565)" will be presented in the Head and Neck Cancer general poster session on Sunday June 6th from 8:00AM until 12:00PM in S Hall A2. This study indicates improved outcomes in terms of locoregional response with the addition of nimotuzumab and is consistent with randomized clinical data in this indication being presented at the same setting.

    About YM BioSciences

    YM BioSciences Inc. is a life sciences product development company. Together with the products from YM BioSciences Australia, the Company is currently developing four late-stage products: nimotuzumab, an EGFR-targeting Affinity-Optimized Antibody(TM); CYT387, a JAK 1/2 small molecule inhibitor; CYT997, a potent, vascular disrupting agent (VDA); and AeroLEF(R), a proprietary, inhaled-delivery composition of free and liposome-encapsulated fentanyl. YM has proven regulatory and clinical trial expertise and a diversified business model designed to reduce risk while advancing clinical products toward international approval, marketing and commercialization.

    Nimotuzumab is a humanized monoclonal antibody in development worldwide, targeting multiple tumor types primarily in combination with radiation and chemoradiation. It is importantly differentiated from all other currently marketed EGFR-targeting agents due to its remarkably benign side-effect profile. Nimotuzumab's anti-tumor activity has led to its approval for marketing in 23 countries. In more than 9,000 patients reported as having been treated with nimotuzumab worldwide to date, Grade IV incidents of radiation dermatitis and incidents of severe rash have been only rarely observed and reports of the other severe side-effects that are typical of EGFR-targeting molecules have been equally rare. Nimotuzumab is licensed to YM's majority-owned, Canadian subsidiary, CIMYM BioSciences Inc., by CIMAB S.A., and was developed at the Center of Molecular Immunology. The clinical stage products discovered by Cytopia Ltd (YM Australia since January 2010) include the JAK 1/2 inhibitor, CYT387, and the novel VDA molecule, CYT997. Both were developed internally at Cytopia from research led by Dr. Andrew Wilks who discovered and named the Janus kinases. Cytopia's earlier stage portfolio includes a JAK3 program that was the subject of a research collaboration underwritten by Novartis that concluded in 2009 with any further development residing exclusively with Novartis; an ongoing collaborative research project with the Melbourne-based Cooperative Research Centre for Cancer Therapeutics (CRC CTx) for the development of Cytopia's inhibitors of Focal Adhesion Kinase (FAK), a protein implicated in progression and metastasis of numerous solid tumors; and a novel series of compounds that inhibit the kinase FMS which have been demonstrated to have excellent potency and selectivity. Approximately 4,000 additional novel compounds have been amassed from Cytopia's own research and are being reviewed. YM's other discovery programs include the Intellimab(R) platform of uniquely optimized antibodies designed to selectively target cancer cells resulting in improvements to the safety profiles of antibodies and the consequent prospect of their conjugation to highly potent toxins for safe delivery to tumour tissue. YM is also developing AeroLEF for the treatment of moderate to severe acute pain. The product is differentiated from other approaches using opioids because patients are able to individually control the analgesia required for their differing intensities of pain. AeroLEF has met all endpoints in each of its trials including a randomized Phase II trial and is currently being prepared for late-stage development internationally.

    This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that nimotuzumab will continue to demonstrate a competitive safety profile in ongoing and future clinical trials; that JAK 1/2 and the VDA molecule will generate positive efficacy and safety data in future clinical trials; AeroLEF(R) will continue to generate positive efficacy and safety data in future clinical trials; that and that YM and its various partners will complete their respective clinical trials within the timelines communicated in this release. Except as required by applicable securities laws, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

    YM BioSciences Inc.

    CONTACT: James Smith, the Equicom Group Inc., Tel. (416) 815-0700 x 229,
    Email: jsmith@equicomgroup.com; Thomas Fechtner, the Trout Group LLC, Tel.
    (646) 378-2931, Email: tfechtner@troutgroup.com




    Oncolytics Biotech(R) Inc. Announces Reovirus Research to be Presented at ASCO Annual Meeting

    CALGARY, May 21 /PRNewswire-FirstCall/ -- Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that abstracts covering clinical research with reovirus (REOLYSIN(R)) are available on the American Society of Clinical Oncology (ASCO) website at http://www.asco.org/, and on the Oncolytics website at http://www.oncolyticsbiotech.com/. The research is scheduled to be presented at the ASCO 2010 Annual Meeting in Chicago, IL, June 4-8, 2010.

    The first abstract entitled "A phase I/II study of oncolytic reovirus plus carboplatin/paclitaxel in patients with advanced solid cancers with emphasis on squamous cell carcinoma of the head and neck (SCCHN)," covers a poster presentation of updated results from the REO 011 study. The researchers reported that thirty-one patients (24 males; median age 59 years) with head and neck cancer (n=24), melanoma (n=4), peritoneal/endometrial cancer (n=2), or sarcoma (n=1) received 147 cycles (median 5, range 1-8) of treatment. In the dose-escalation phase of the study, there were no dose-limiting toxicities. Grade 3/4 toxicities included anaemia, leucopenia, neutropenia, lymphopenia, thrombocytopenia, infection and hypotension. Neutralising antireovirus antibody responses will be presented. In the Phase 1 study, partial responses (PR) were noted in two of five patients with head and neck cancer. The Phase 2 study treated head and neck cancer patients at the maximum dose level (3 x 10(10) TCID(50)) in order to further assess tumour response. In total, 19 patients with head and neck cancer received at least two cycles and are evaluable for response. Most were SCCHN refractory to previous platinum-based chemotherapy for recurrent/metastatic disease. PR was seen in eight patients (42%) and stable disease (SD) in six (32%). One additional PR and one SD were observed among four patients with malignant melanoma. The researchers expect final results for median overall survival (OS) and progression free survival (PFS) will be presented.

    The researchers concluded that intravenous administration of reovirus in combination with carboplatin/paclitaxel is a safe and well-tolerated combination with promising anticancer activity in SCCHN. Further evaluation of this combination in a randomized Phase III trial in SCCHN is underway. The poster is expected to be presented in a session on Monday June 7, 2010 from 8:00 am to 12:00 pm CDT.

    The second abstract entitled "Phase II study of reovirus with paclitaxel (P) and carboplatin (C) in patients with metastatic non-small cell lung cancer (NSCLC) who have Kras or EGFR-activated tumors," covers a poster presentation relating to the structure of the Company's REO 016 trial. The poster is expected to be presented in a session on Monday June 7, 2010 from 8:00 am to 12:00 pm CDT.

    The third abstract entitled "Phase I/II trial of reovirus serotype 3-Dearing strain in patients with recurrent ovarian cancer," covers a poster presentation relating to the structure of a National Cancer Institute (NCI) sponsored study for patients with metastatic ovarian, peritoneal and fallopian tube cancers using concurrent intravenous and intraperitoneal administration of REOLYSIN. The poster is expected to be presented in a session on Monday June 7, 2010 from 8:00 am to 12:00 pm CDT.

    About Oncolytics Biotech Inc.

    Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of human trials including a Phase III trial in head and neck cancers using REOLYSIN, its proprietary formulation of the human reovirus. For further information about Oncolytics, please visit: http://www.oncolyticsbiotech.com/.

    This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the implication of the abstracts and materials presented on the ASCO website and at this meeting with respect to REOLYSIN, and the Company's belief as to the potential of REOLYSIN as a cancer therapeutic, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN as a cancer treatment, the tolerability of REOLYSIN outside a controlled test, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize REOLYSIN, uncertainties related to the research and development of pharmaceuticals and uncertainties related to the regulatory process. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements, except as required by applicable laws.

    Oncolytics Biotech Inc.

    CONTACT: The Equicom Group, Nick Hurst, 300 5th Ave. SW, 10th Floor,
    Calgary, Alberta, T2P 3C4, Tel: (403) 218-2835, Fax: (403) 218-2830,
    nhurst@equicomgroup.com; The Investor Relations Group, Erika Moran, 11 Stone
    St, 3rd Floor, New York, NY 10004, Tel: (212) 825-3210, Fax: (212) 825-3229,
    emoran@investorrelationsgroup.com




    Rentrak Announces Top Ten Movies-on-Demand Titles Week Ending May 16, 2010

    PORTLAND, Ore., May 21 /PRNewswire-FirstCall/ -- Rentrak Corporation today announced the top ten movies-on-demand (VOD) titles based on consumer transaction rate. Movies-on-demand are transactional (pay-per-purchase) films available through cable and telco providers.

    According to the company's OnDemand Essentials service, the top ten most-viewed titles, per data collected from May 9, 2010 through May 16, 2010 include:

    Rentrak Top Ten VOD Titles -------------------------- BOX VOD RELEASE MPAA OFFICE RANK TITLE STUDIO DATE RATING ($M) 1 Avatar Fox 5/09/10 PG-13 748.0 Edge of Warner Bros. 2 Darkness* 5/11/10 R 43.3 3 Tooth Fairy Fox 5/11/10 PG 59.8 4 Daybreakers* Lionsgate 5/11/10 R 30.1 It's Universal 5 Complicated* 4/27/10 R 112.7 6 Leap Year* Universal 5/04/10 PG 25.9 The Lovely Paramount 7 Bones* (NYSE: VIA; VIA.B) 4/20/10 PG-13 44.0 8 The Blind Side* Warner Bros. 3/23/10 PG-13 255.1 Alvin and Chipmunks: The Fox 9 Squeakquel 4/06/10 PG 219.5 10 2012 Sony 4/01/10 PG-13 166.1 Source: Rentrak OnDemand Essentials, as dated, rank based on Transaction Rate. OnDemand Essentials includes reporting from Operator partners on Television On-Demand usage. * Indicates day-and-date with home video release.

    © Rentrak Corporation 2010 - Content in this chart is produced and/or compiled by Rentrak Corporation and its OnDemand Essentials data collection and analytical service, and is covered by provisions of the Copyright Act. The material presented herein is intended to be available for public use. You may reproduce the content of the chart in any format or medium without first obtaining permission, subject to the following requirements: (1) the material must be reproduced accurately; and (2) any publication or issuance of any part of the material to others must acknowledge Rentrak Corporation as the source of the material.

    About OnDemand Essentials®

    OnDemand Essentials, a service of Rentrak's Advanced Media & Information Division, provides operators, content providers (including broadcast/cable networks, studios) and advertisers with a transactional tracking and reporting system to view and analyze on-demand content. The product is an extension of Rentrak's Essentials suite of business intelligence products customized for the entertainment industry. OnDemand Essentials clients have password protected, near real-time, Web browser-based 24/7 access to on-demand consumer usage data at various access levels based on business and privacy rules. A sophisticated toolset aggregates and reports data across multiple vendors in one easy to use report system. Clients using the OnDemand Essentials system are able to instantly analyze and interpret their own business data to identify trends, program and promote more effectively, as well as track their performance against the broader business sector in which they operate.

    About Rentrak Corporation

    Rentrak Corporation is a global digital media measurement and research company, serving the most recognizable companies in the entertainment industry. With a reach across numerous platforms including box office, home entertainment, on-demand and linear television, broadband and mobile, Rentrak is headquartered in Portland, Oregon, with additional offices worldwide in Los Angeles, New York City, Miami/Ft. Lauderdale, Argentina, Australia, Canada, France, Germany, Mexico, Spain and the United Kingdom. For more information on any of Rentrak's services, please visit http://www.rentrak.com/.

    Contacts: Rogers & Cowan for Rentrak Corporation Sallie Olmsted Amanda Bialek (310) 854-8124 (310) 854-8151 solmsted@rogersandcowan.com abialek@rogersandcowan.com

    Rentrak Corporation

    CONTACT: Sallie Olmsted, +1-310-854-8124, solmsted@rogersandcowan.com,
    or Amanda Bialek, +1-310-854-8151, abialek@rogersandcowan.com, both of Rogers
    & Cowan for Rentrak Corporation

    Web Site: http://www.rentrak.com/




    Anadys Announces Completed 12-Week Results From Phase II Combination Study of ANA598 With Interferon and RibavirinAntiviral Potency, Durability and Safety Results Confirm Compelling Profile Company to Review Data During Conference Call at 8:30 AM EDT Today

    SAN DIEGO, May 21 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. today announced completed 12-week results from an ongoing Phase II study, which demonstrated that 75% of hepatitis C patients treated with 400 mg ANA598 twice daily (bid) in combination with pegylated interferon and ribavirin (current standard of care, or SOC) achieved undetectable levels of virus (<15 IU/mL) at week 12, known as complete Early Virological Response or cEVR.

    "We are very pleased with the comparable antiviral potency and favorable safety profile demonstrated through 12 weeks for both doses investigated in this study," said Steve Worland, Ph.D., President and CEO of Anadys. "Coupled with the favorable tolerability profile seen at 200 mg bid, we believe that these results establish ANA598 at 200 mg bid as one of the most attractive agents in Phase 2 HCV development today."

    Anadys also announced additional data for patients in the 200 mg bid dose group who have now completed 24 weeks of treatment - 12 weeks of ANA598 in combination with SOC, followed by an additional 12 weeks of SOC alone. At the 200 mg bid dose level, where 73% of patients achieved a cEVR, 17 of 18 patients who had undetectable levels of virus at week 12 and continued on SOC for an additional 12 weeks remained undetectable at 24 weeks. Additionally, two patients who had low but detectable levels of virus at week 12 achieved undetectable levels of virus at week 24.

    Antiviral Response Through 12 Weeks Proportion of Patients (%) with Undetectable Levels of Virus (<15 IU/mL) by Week ------------------------------------------------------ Week 1 Week 2 Week 3 Week 4 Week 6 Week 8 Week 10 Week 12 ANA598 + SOC 11 22 44 56 65 69 73 73 200 mg bid ANA598 + SOC 9 27 30 42 56 72 75 75 400 mg bid Placebo + SOC 0 3 9 13 19 38 48 63

    In the second cohort a single patient who received ANA598 400 mg bid experienced viral breakthrough (defined as a confirmed increase of >1 log from any prior measurement) between weeks 10 and 12. No other patient who received either dose of ANA598 experienced viral breakthrough.

    IL28B Genotyping-Preliminary Assessment

    Based on a preliminary assessment of IL28B genotyping from approximately sixty percent of the patients in the Phase II study, Anadys can now offer additional perspective on the response of the patients who received placebo plus standard of care (control arm) in the study. Recent scientific studies have shown that individuals with the IL28B CC genotype, present in approximately 37% of Caucasian HCV patients and a lower percentage of patients in other ethnic groups, are substantially more responsive to SOC than patients with other IL28B genotypes. In the SOC control arm of the ANA598 study, 56% of the patients who have been genotyped to date are of the CC genotype while in the ANA598-treated arms only 21% of the patients who have been genotyped to date are of the CC genotype. Anadys believes that the high proportion of CC patients in the SOC control arm of the ANA598 Phase II study relative to the overall population likely contributed to a higher cEVR rate than has been seen historically.

    Preliminary Safety and Tolerability Assessment Through 12 Weeks

    Both doses of ANA598 demonstrated a favorable safety and tolerability profile through 12 weeks, although conclusions regarding safety and tolerability cannot be made until results in more patients and potentially over longer duration are known. Safety laboratory values were comparable between the ANA598 and control arms. At the 200 mg bid dose level, the incidence of all adverse events was similar between the active and control arms, with reported adverse events being typical for patients treated with interferon and ribavirin. In the 400 mg bid arm, a higher incidence of rash (mostly mild) was seen relative to the 200 mg bid and control arms. The incidence of all other adverse events was comparable between the 400 mg bid and control arms. In the 400 mg bid arm, 59% of patients (20/34) receiving ANA598 400 mg bid developed rash, compared to 41% (12/29) receiving 200 mg bid and 31% (10/32) for patients that received placebo plus SOC. In the 400 mg bid group, 16 of 20 rashes were mild, with one grade 2 rash and three grade 3 rashes. As previously reported, in the 200 mg bid arm, the incidence of rash was comparable with the placebo control arm and also consistent with historical reports of rash incidence due to interferon and ribavirin.

    Phase II Combination Study

    In the ongoing Phase II study, a total of approximately 90 treatment-naïve genotype 1 patients have received ANA598 or placebo in combination with Pegasys® (peginterferon alfa-2a) and Copegus® (ribavirin, USP) for 12 weeks at dose levels of 200 mg bid or 400 mg bid, each with a loading dose of 800 mg bid on day one. After week 12, patients are to continue receiving SOC. Patients who achieved undetectable levels of virus at weeks 4 and 12 are to be randomized to stop all treatment at week 24 or 48. The primary endpoint of the study is the proportion of patients who achieve undetectable levels of virus at week 12 (defined as complete Early Virological Response, or cEVR). Additional endpoints include safety and tolerability as well as the proportion of patients with undetectable levels of virus at week 4 (defined as Rapid Virological Response, or RVR). Patients will be followed for 24 weeks after stopping therapy to determine the rate of Sustained Virological Response, or SVR. Approximately 90 patients have been enrolled in this study - with approximately 30 patients receiving ANA598 plus SOC at each dose level and 30 patients receiving placebo plus SOC. The study is being managed by the Duke Clinical Research Institute (DCRI) under the leadership of John McHutchison, M.D. and is being conducted at a number of clinical sites in the United States.

    About ANA598

    ANA598 is a non-nucleoside inhibitor of the HCV RNA polymerase and is wholly owned by Anadys. Anadys has completed three Phase I clinical studies of ANA598 that have demonstrated potent antiviral activity and good tolerability. In a monotherapy study in treatment-naïve genotype 1 patients, treatment with ANA598 for three days led to median end-of-treatment declines in viral load ranging from 2.4 to 2.9 log10 in three separate dose groups. No patient at any dose level in the monotherapy study showed evidence of viral breakthrough while on ANA598, and there were no serious adverse events. Those patients from the monotherapy study who subsequently received pegylated interferon and ribavirin all exhibited further viral load decline, demonstrating that viral variants revealed by brief treatment with ANA598 remain susceptible to current SOC, consistent with prior in vitro results.

    Anadys has completed two long-term chronic toxicology studies of ANA598 (26 weeks duration in rats and 39 weeks duration in monkeys). The No Observed Adverse Effect Level, or NOAEL, is 1000 mg/kg, the highest dose tested, in both the rat and monkey. The completed toxicology studies support the ongoing Phase II clinical study as well as future clinical studies of longer duration.

    Anadys has presented in vitro data supporting the use of ANA598 in combination with interferon-alpha as well as with other anti-HCV agents currently in development that act through diverse mechanisms. In particular, data has shown that ANA598 is synergistic in vitro with interferon-alpha as well as representative HCV protease and polymerase inhibitors. In vitro combination treatment at clinically relevant concentrations of interferon-alpha and ANA598 results in clearance of HCV RNA from cells rather than selection of resistant isolates. Furthermore, ANA598 retains full activity in vitro against mutations conferring resistance to protease inhibitors, nucleoside polymerase inhibitors and non-nucleoside polymerase inhibitors that act at binding sites distinct from that of ANA598, while protease and nucleoside polymerase inhibitors retain full activity in vitro against mutations conferring resistance to ANA598.

    ANA598 has received Fast Track Status from the FDA for the treatment of chronic hepatitis C.

    Conference Call Webcast and Slides

    Anadys will hold a conference call and webcast today, Friday, May 21, 2010 at 8:30 a.m. Eastern Daylight Time to discuss the completed 12 week results for ANA598 from the ongoing Phase II combination study. A live webcast of the call, including accompanying slides, will be available online at http://www.anadyspharma.com/. A telephone replay with slides will also be available approximately one hour after completion of the call. To access the telephone replay, dial 888-286-8010 (domestic) or 617-801-6888 (international), passcode 75833750. The webcast and telephone replay will be available through June 4, 2010.

    Safe Harbor Statement

    Statements in this press release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, references to (i) the compelling profile of ANA598 based on the antiviral potency, durability and safety results seen to date; (ii) the belief that the study results announced today establish ANA598 at 200 mg bid as one of the most attractive agents in Phase 2 HCV development today; (iii) the belief, based on a partial data set, that the high proportion of CC patients in the SOC control arm of the ANA598 Phase II study relative to the overall population likely contributed to a higher cEVR rate in the control arm than has been seen historically; and (iv) the ability for patients to achieve an SVR in the Phase II combination study. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause Anadys' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. For example, the results of preclinical and early clinical studies may not be predictive of future results, and Anadys cannot provide any assurances that ANA598 will not have unforeseen safety issues or will continue to have favorable results as the Phase II trial progresses. In addition, Anadys' results may be affected by competition from other biotechnology and pharmaceutical companies, its effectiveness at managing its financial resources, its ability to enter into transactions around its product candidates, its ability to successfully develop and market products, difficulties or delays in its preclinical studies or clinical trials, difficulties or delays in manufacturing its clinical trials materials, the scope and validity of patent protection for its products, regulatory developments and its ability to obtain additional funding to support its operations. Risk factors that may cause actual results to differ are more fully discussed in Anadys' SEC filings, including Anadys' Form 10-K for the year ended December 31, 2009 and Form 10-Q for the quarter ended March 31, 2010. All forward-looking statements are qualified in their entirety by this cautionary statement. Anadys is providing this information as of this date and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

    Pegasys® and Copegus® are registered trademarks of Hoffman-La Roche Inc.

    Anadys Pharmaceuticals, Inc.

    CONTACT: Investors, Amy Conrad of Anadys Pharmaceuticals, Inc.,
    +1-858-530-3607, aconrad@anadyspharma.com; or Media, Ian Stone,
    ian.stone@russopartnersllc.com, or David Schull,
    david.schull@russopartnersllc.com, both of Russo Partners, LLC,
    +1-619-528-2220, for Anadys Pharmaceuticals, Inc.

    Web Site: http://www.anadyspharma.com/




    Eight Aspiring Professional Gamers Win Big in Chicago at Second Doritos MLG Pro-Gaming CombineAmateur Gaming Competition Lets Fans Train and Test Skills for a Chance to Compete Alongside the Greatest Names in Gaming

    CHICAGO and NEW YORK, May 21 /PRNewswire/ -- Eight video game fans broke through a field of more than 1,000 game players aspiring to become professional video gamers at the second stop of the 2010 Doritos MLG Pro-Gaming Combine in Chicago this past weekend, a four-city tour of the first-ever nationwide skills challenge in competitive video gaming history.

    The Combine - which was created with Doritos to inspire fans to pursue their gaming passions and showcase their talents at the highest levels - brought together thousands of video game amateurs with MLG Pros and League officials across America. Aspiring professional gamers were given a rigorous testing ground to showcase their skills, and an opportunity to further gain exposure through MLG's thriving community of players. The winners will now travel to Columbus to compete alongside the best gamers in the world at the MLG Pro Circuit event June 4-6.

    The Chicago winners are: -- Free For All (FFA) winner: 15-year-old Jordan "Amish Acorns" Dotzel from Mountaintop, PA. -- Winning 4v4 team: "Victorious Secret" with featured players: -- 18 yr old Timothy "Adrenaline" Keane from Queens, NY; winner of Nashville Combine FFA competition -- 19 yr old Alejandro "Swiftkill" Ramirez from San Juan, TX -- 19 yr old Brendan "Fugo" Fugo from Chapel Hill, NC -- 19 yr old Zachary "Revamp" Edwards from Dayton, OH -- Wild Card Winners: -- 18 yr old Jonathan "AczDc" Harlow of team Escape from Livonia, MI -- 17 yr old Nathan "Google Nate" Cava of team Pluto is a Planet from Canton, MI -- 15 yr old Joey "Twin Savior" Gargaro of team UoR Livin' The Dream from Naperville, IL

    Over the course of the weekend, more than 1,000 players played nearly 550 games and were evaluated by the league in key areas including: communication, accuracy, decision-making and situational performance. Approximately 400 players who exhibited superior performance in those categories were identified by the MLG Scout Team, and put through additional competitions and tests to separate out the players with professional-league potential. The eight winners each received:

    -- $500 in prize money. -- An invitation to compete for Pro Status in the Finals Event. -- Round Trip Airfare ($500 Limit) to the Pro Circuit National Championship Competition and a three-night stay in the Pro Circuit National Championship Competition Hotel booked by Major League Gaming (provided that winner maintains his or her eligibility status for the Finals Event). MLG will have the option of either booking the airfare for winner or providing winner with a $500 airfare stipend (or cash) at the upcoming Pro Circuit Competition. -- Free Entry into the upcoming Halo 3 Pro Circuit Event and the opportunity to purchase a Reserved Team Pass for that Event. -- A Profile page on the Doritos Pro-Gaming Combine Web site. -- Editorial Coverage at the upcoming Pro Circuit Competition. -- The ability to play on a Feature Station, at the upcoming Pro Circuit Competition, dedicated to matches featuring Combine Winners.

    The series of nationwide Combine events will culminate at the Finals Event at the 2010 MLG Pro Circuit National Championship, the date and location of which has yet to be announced. Four players will receive MLG pro status at that time. The remaining two Doritos MLG Pro-Gaming Combines are:

    -- July 23-26, 2010 -- Denver, Colo. -- October 15-17, 2010 -- Washington, D.C.

    "Coming out of our second Doritos MLG Pro-Gaming Combine event, we were thrilled to see the caliber of amateur gamers who came to showcase their skills. I'm excited to see how this group performs in Columbus as they continue along the path towards making their professional gaming dreams a reality," said Sundance DiGiovanni, co-founder and interim CEO of Major League Gaming.

    Full details about the event are available at http://www.doritoscombine.com/, including specifics about the Combine format and other events.

    ABOUT MAJOR LEAGUE GAMING

    Founded in 2002, Major League Gaming (MLG) is the dominant media property exclusively targeting the approximately 40 million consumers in North America who have a passion for playing video games as a competitive social activity. The company exclusively represents the best professional gamers and gives millions of aspiring gamers around the world an opportunity to compete, improve their skills, and socialize through our thriving online competitive community and live Pro Circuit competitions. For more information: http://www.mlgpro.com/.

    ABOUT FRITO-LAY

    Doritos tortilla chips is one of the many brands that make up Frito-Lay North America, the $13 billion convenient foods business unit of PepsiCo , which is headquartered in Purchase, NY. Learn more about Frito-Lay at the corporate Web site, http://www.fritolay.com/, the Snack Chat blog, http://www.snacks.com/ and on Twitter at http://www.twitter.com/fritolay.

    PepsiCo offers the world's largest portfolio of billion-dollar food and beverage brands, including 19 different product lines that each generates more than $1 billion in annual retail sales. Our main businesses - Frito-Lay, Quaker, Pepsi-Cola, Tropicana and Gatorade - also make hundreds of other nourishing, tasty foods and drinks that bring joy to our consumers in more than 200 countries. With annualized revenues of nearly $60 billion, PepsiCo's people are united by our unique commitment to sustainable growth, called Performance with Purpose. By dedicating ourselves to offering a broad array of choices for healthy, convenient and fun nourishment, reducing our environmental impact, and fostering a diverse and inclusive workplace culture, PepsiCo balances strong financial returns with giving back to our communities worldwide. In recognition of its continued sustainability efforts, PepsiCo was named for the third time to the Dow Jones Sustainability World Index (DJSI World) and for the fourth time to the Dow Jones Sustainability North America Index (DJSI North America) in 2009. For more information, please visit http://www.pepsico.com/

    Contacts: Amy Janzen Major League Gaming 917-209-6819 ajanzen@mlgpro.com Chris Kuechenmeister Frito-Lay 972-334-2044 Chris.kuechenmeister@fritolay.com

    Major League Gaming

    CONTACT: Amy Janzen, Major League Gaming, +1-917-209-6819,
    ajanzen@mlgpro.com; or Chris Kuechenmeister, Frito-Lay, +1-972-334-2044,
    Chris.kuechenmeister@fritolay.com

    Web Site: http://www.mlgpro.com/




    Sembcorp Commences Tender Offer to Acquire All Outstanding Shares of Cascal for US$6.75 Per Share in Cash

    SINGAPORE, May 21 /PRNewswire-Asia/ -- Sembcorp Industries Ltd (Sembcorp) today announces that its wholly-owned subsidiary, Sembcorp Utilities Pte Ltd (Sembcorp Utilities) has commenced a tender offer for all of the issued and outstanding common shares of Cascal N.V. (Cascal) , a New York Stock Exchange-listed company and leading provider of water and wastewater services, for an offer price of US$6.75 per share if at least 80% of the issued and outstanding Shares of Cascal on a fully diluted basis are validly tendered and not withdrawn (the "80% Condition"). The tender offer is being made pursuant to an Offer to Purchase, dated May 21, 2010, and in connection with the previously announced Tender Offer and Stockholder Support Agreement, dated April 26, 2010, among Sembcorp Utilities, Biwater Investments Ltd. (Biwater), the majority stockholder of Cascal, and Biwater Holdings Limited, the ultimate parent company of Biwater, pursuant to which Sembcorp Utilities agreed to launch a tender offer to acquire all of the outstanding common shares of Cascal, and Biwater agreed to promptly and validly tender its 17,868,543 shares of Cascal (representing approximately 58.4% of the outstanding common shares of Cascal, based on the 30,581,343 Shares reported by Cascal to be issued and outstanding as of December 31, 2009) in the tender offer.

    The offer and withdrawal rights will expire at 11:00 a.m. New York City time on Monday, June 21, 2010, unless extended.

    Pursuant to the terms of the tender offer, Sembcorp Utilities is offering to acquire all the common shares of Cascal at a price of US$6.75 per share. The consummation of the tender offer is conditioned on the 80% Condition being satisfied. Upon Biwater's tender of its shares pursuant to the Tender Offer and Stockholder Support Agreement, 17,868,543 shares, or approximately 58.4% of the issued and outstanding shares of Cascal (based on the 30,581,343 Shares reported by Cascal to be issued and outstanding as of December 31, 2009) will have been tendered in the offer. Accordingly, the 80% Condition to the tender offer will be satisfied if approximately an additional 21.6% (or 6,596,532 shares based on the 30,581,343 shares reported by Cascal to be issued and outstanding as of December 31, 2009) of the issued and outstanding shares are validly tendered and not withdrawn in the tender offer. If at the time of the scheduled expiration of the tender offer, less than 80% of the outstanding common shares of Cascal on a fully diluted basis have been validly tendered and not withdrawn in the tender offer, Sembcorp Utilities will (i) reduce the tender offer price to US$6.40 per share, (ii) reduce the 80% Condition to provide that consummation of the tender offer is conditioned on at least 17,868,543 shares (the number of shares Biwater has agreed to tender) being validly tendered and not withdrawn in the tender offer and (iii) extend the tender offer for ten business days. The tender offer is also subject to other customary conditions for transactions of this nature.

    Sembcorp Utilities' all-cash offer is not subject to a financing condition.

    IMPORTANT NOTICE: This press release is for informational purposes only and is not an offer to buy or the solicitation of an offer to sell any common shares of Cascal. The Offer to Purchase, Letter of Transmittal and related documents will be filed today with the U.S. Securities and Exchange Commission, will be mailed to Cascal shareholders and will also be made available for distribution to beneficial owners of Cascal common shares. The solicitation of offers to buy common shares of Cascal will only be made pursuant to the Offer to Purchase, the Letter of Transmittal and related documents. Cascal shareholders are strongly advised to read both the tender offer statement and the solicitation/recommendation statement regarding the tender offer when they become available as they will contain important information, including the various terms of, and conditions to, the tender offer.

    The tender offer statement will be filed today by Sembcorp Utilities with the U.S. Securities and Exchange Commission, and the solicitation/recommendation statement will be filed by Cascal with the U.S. Securities and Exchange Commission. Investors and stockholders may obtain free copies of these statements (when available) and other documents filed by Sembcorp Utilities and Cascal at the U.S. Securities and Exchange Commission's website at http://www.sec.gov/. Cascal's stockholders may obtain copies of all of the offering documents free of charge at the SEC's website (http://www.sec.gov/) or by directing a request to MacKenzie Partners, Inc., the Information Agent for the offer, at 212-929-5500 or toll-free at 800-322-2885. The tender offer will expire at 11:00 a.m. New York City time on June 21, 2010, unless extended in the manner set forth in the Offer to Purchase. Investors and stockholders should seek legal or other professional advice before acting or relying on any of the information provided above.

    ABOUT SEMBCORP INDUSTRIES

    Sembcorp Industries is a leading energy, water and marine group. With facilities with over 3,800 megawatts of power capacity and over four million cubic meters of water per day in operation and under development, Sembcorp is a trusted provider of essential energy and water solutions to customers in Singapore, the UK, China, Vietnam, the UAE and Oman.

    Aside from its energy and water business, the Sembcorp Industries Group also encompasses a world leader in marine & offshore engineering, as well as an established provider of environmental services and developer of integrated townships and industrial parks. The Group has total assets of over S$9 billion and employs more than 6,700 employees. Listed on the main board of the Singapore Exchange, it is a component stock of the Straits Times Index and several MSCI indices.

    ABOUT SEMBCORP'S WATER BUSINESS

    Competitive and technologically advanced water solutions are core to Sembcorp's utilities service offering. Globally, Sembcorp owns and manages water facilities with a combined capacity of over four million cubic meters per day in operation and under development serving both municipal and industrial customers.

    Sembcorp's broad expertise in wastewater treatment encompasses the ability to treat highly concentrated wastewater and high salinity wastewater discharged by industries, using advanced biological treatment processes. Furthermore, it is able to reclaim high grade industrial water, demineralised water and potable water from treated effluent. Through treating wastewater and recovering usable water from the effluent which can in turn be supplied back to customers, Sembcorp's facilities are able to minimise liquid discharge and promote a sustainable alternative water supply.

    The company also has expertise in both reverse osmosis and thermal processes for seawater desalination and provides water for industrial use to customers in petrochemical and chemical zones. These include demineralised water, industrial water, raw water, chilled water, cooling water and seawater cooling.

    Sembcorp Industries Ltd

    CONTACT: For Singapore: Ng Lay San (Ms), Vice President, Group Corporate
    Relations at +65-6723-3150 or ng.laysan@sembcorp.com; Lim Yuan See (Ms),
    Associate Director, Singapore, Kreab Gavin Anderson at +65-6339-9110 or
    ylim@kreabgavinanderson.com; Fock Siu Ling (Ms), PR Counsel, Group Corporate
    Relations at +65-6723-3152 or fock.siuling@sembcorp.com; For US: Richard A.
    Mahony (Mr), Managing Partner, New York, Kreab Gavin Anderson at
    +1-212-515-1960 or rmahony@kreabgavinanderson.com; For UK: Natalie Biasin (Ms),
    Associate Director, London, Kreab Gavin Anderson at +44-20-7074-1864 or
    nbiasin@kreabgavinanderson.com




    DuPont Titanium Technologies annonce une hausse des prix pour les produits en dioxyde de titane Ti-Pure(R) sur les marchs d'Europe, du Moyen-Orient et d'Afrique

    WILMINGTON, Delaware, May 21, 2010 /PRNewswire/ --

    DuPont Titanium Technologies annonce une augmentation du prix de toutes ses qualits de dioxyde de titane (TiO2) DuPont(TM) Ti-Pure(R) vendues sur les marchs d'Europe, du Moyen-Orient et d'Afrique.

    À compter du 1er juillet 2010, ou selon les conditions stipules dans les contrats, les prix nets sur les marchs en euros d'Europe de l'Ouest et Centrale et d'Afrique du Nord augmenteront de 150 euros par tonne mtrique. Cette augmentation s'ajoute la hausse prcdemment annonce pour le 1er juin 2010.

    À compter du 1er juillet 2010, ou selon les conditions stipules dans les contrats, les prix nets sur les marchs en dollars amricains d'Europe de l'Est, du Moyen-Orient et d'Afrique subsaharienne augmenteront de 150 USD par tonne mtrique. Cette augmentation s'ajoute la hausse prcdemment annonce pour le 1er juin 2010.

    DuPont Titanium Technologies, le plus important fabricant de produits en dioxyde de titane au monde, rpond aux besoins de ses clients internationaux dans les secteurs des revêtements, du papier et du plastique. La socit exploite des usines DeLisle (Mississippi), New Johnsonville (Tennessee), Edge Moor (Delaware), Altamira (Mexique) et Kuan Yin (Taiwan). Toutes ces installations utilisent un procd de fabrication au chlorure. La socit exploite galement une mine Starke (Floride). Les centres d'assistance technique, qui servent les marchs de l'Amrique latine, de l'Europe, du Moyen-Orient, de l'Asie et de l'Amrique du Nord, se trouvent Paulinia (Brsil), Mexico City (Mexique), Mechelen (Belgique), Dzerzhinskiy (Russie), Kuan Yin (Taiwan), Ulsan (Core), Shanghai (Chine) et Wilmington (Delaware).

    DuPont est une socit de services et de produits bass sur la science. Fonde en 1802, DuPont fait appel la science pour crer des solutions durables et essentielles pour permettre aux personnes dans le monde entier de profiter d'une vie meilleure, plus sûre et en meilleure sant. DuPont, qui exerce ses activits dans environ 80 pays, offre une vaste gamme de produits et de services novateurs pour divers marchs tels que ceux de l'agriculture et de l'alimentation, du btiment et de la construction, des communications et du transport.

    Les logos ovale de DuPont, DuPont(TM), The miracles of science(TM) et Ti-Pure(R) sont des marques commerciales ou des marques commerciales dposes de DuPont ou de ses filiales.

    Contact : Kimberlie A. Lantz +1-302-999-2361 kimberlie.a.lantz@usa.dupont.com

    DuPont Titanium Technologies

    Kimberlie A. Lantz de DuPont, +1-302-999-2361, kimberlie.a.lantz@usa.dupont.com




    Naturally Advanced Technologies Raises $1.4 Million

    PORTLAND, OR, May 21 /PRNewswire-FirstCall/ -- Naturally Advanced Technologies Inc. (OTCBB: NADVF; TSXV: NAT) (the "Company") closed the non-brokered private placement, announced on May 18th, pursuant to which it has now issued from treasury 1,424,739 units (each a "Unit") of the Company, at a subscription price of $1.00 per Unit, and for gross proceeds of $1,424,739 (the "Private Placement").

    Each Unit of the Private Placement is comprised of one common share and one-half of one share purchase warrant (each a "Warrant") of the Company, with each whole Warrant entitling the subscriber thereof to acquire one additional common share (each a "Warrant Share") of the Company at an exercise price of $1.25 per Warrant Share up to and including May 19, 2013.

    All Shares issued pursuant to the Private Placement and any Warrant Shares issued in connection with the exercise of any of the Warrants, if any, are subject to a hold period expiring on September 20, 2010, in accordance with the policies of the TSX Venture Exchange and applicable securities laws.

    Finder's fees of $59,500 in cash have now been paid in conjunction with the closing of the Private Placement.

    Proceeds of the Private Placement will be used to advance the development of the Company's business and for general corporate and working capital purposes.

    About Naturally Advanced Technologies Inc.

    Naturally Advanced Technologies Inc. is committed to unlocking the potential of renewable and environmentally sustainable biomass resources from hemp and other bast fibers. The Company, through its wholly owned subsidiary, Crailar Fiber Technologies Inc., is developing proprietary technologies for production of bast fibers, cellulose pulp, and their resulting by-products, in collaboration with Canada's National Research Council and the Alberta Research Council. CRAiLAR(R) technology offers cost-effective and environmentally sustainable processing and production of natural, bast fibers such as hemp and flax, resulting in increased performance characteristics for use in textile, industrial, energy, medical and composite material applications. The Company was founded in 1998 as a provider of environmentally friendly, socially responsible clothing and adheres to a "triple bottom line" philosophy, respecting the human rights of employees, the environmental impact of the Company's operations and fiscal responsibility to its shareholders. See http://www.naturallyadvanced.com/.

    Neither the TSX Venture Exchange Inc. nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

    Forward-Looking Statement Disclaimer

    This news release includes certain statements that may be deemed "forward-looking statements". All statements in this news release, other than statements of historical facts, are forward-looking statements. Forward-looking statements or information are subject to a variety of risks and uncertainties which could cause actual events or results to differ from those reflected in the forward-looking statements or information and including, without limitation, risks and uncertainties relating to: any market interruptions that may delay the trading of the Company's shares, technological and operational challenges, needs for additional capital, changes in consumer preferences, market acceptance and technological changes, dependence on manufacturing and material supplies providers, international operations, competition,regulatory restrictions and the loss of key employees. In addition, the Company's business and operations are subject to the risks set forth in the Company's most recent Form 10-K, Form 10-Q and other SEC filings which are available through EDGAR at http://www.sec.gov/. These are among the primary risks we foresee at the present time. The Company assumes no obligation to update the forward-looking statements.

    Naturally Advanced Technologies Inc.

    CONTACT: Investor Contact: Kirsten Chapman, Cathy Mattison
    Lippert/Heilshorn & Associates, (415) 433-3777, ir@naturallyadvanced.com;
    Media Contact: Cheryl Roth, Megan Roarty, organicworks PR, (212) 253-0474,
    Cheryl@organicworkspr.com, Megan@organicworkspr.com




    AerCap Signs Debt Facilities for Total of $190 Million With Three Banks From Europe and Asia

    AMSTERDAM, May 21 /PRNewswire-FirstCall/ -- AerCap Holdings N.V. ("AerCap"), today announced that it has signed debt facility agreements totaling $190 million. The facilities have terms ranging from eight to ten years and cover the financing of A319, A321 and A330 aircraft. The separate facilities were provided individually by Credit Agricole CIB, DBS Bank Singapore and Sumitomo Mitsui Banking Corporation (SMBC).

    AerCap's CFO, Keith Helming, said: "We are delighted to be expanding AerCap's broad network in the financial community with DBS Bank from Singapore, a new business partner for us, and to build up on our already strong relationships with Credit Agricole CIB and SMBC."

    Including the new facilities, AerCap has now closed $560 million of new debt in 2010 which brings the total amount of debt accessed by the company in the last two years to $5.5 billion.

    About AerCap Holdings N.V.

    AerCap is the world's leading independent aircraft leasing company. AerCap also provides engine leasing, aircraft management services, aircraft maintenance, repair and overhaul services and aircraft disassemblies. AerCap is headquartered in The Netherlands and has offices in Ireland, the United States, China, Singapore and the United Kingdom.

    This press release may contain forward-looking statements that involve risks and uncertainties. In most cases, you can identify forward-looking statements by terminology such as "may", "should", "expects", "plans", "anticipates", "believes", "estimates", "predicts", "potential" or "continue" or the negative of such terms or similar terminology. Such forward-looking statements are not guarantees of future performance and involve significant assumptions, risks and uncertainties, and actual results may differ materially from those in the forward-looking statements.

    Contact for Media: Contact for Investors: Frauke Oberdieck Peter Wortel +31 20 655 9616 +31 20 655 9658 foberdieck@aercap.com pwortel@aercap.com

    AerCap Holdings N.V.

    CONTACT: Media: Frauke Oberdieck, +31-20-655-9616,
    foberdieck@aercap.com, or Investors: Peter Wortel, +31-20-655-9658,
    pwortel@aercap.com, both of AerCap Holdings N.V.

    Web Site: http://www.aercap.com/

    page 1     page 2     page 3     page 4     page 5     page 6     page 7    

    News archive of December 2014
    1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31 



    News Archives of May 2010
    1   2   3   4   5   6   7   8   9   10   11   12   13   14   15   16   17   18   19   20   21   22   23   24   25   26   27   28   29   30   31  

    News Archives other dates
        2014:   Jan     Feb     Mar     Apr     May     Jun     Jul     Aug     Sep     Oct     Nov     Dec    
        2013:   Jan     Feb     Mar     Apr     May     Jun     Jul     Aug     Sep     Oct     Nov     Dec    
        2012:   Jan     Feb     Mar     Apr     May     Jun     Jul     Aug     Sep     Oct     Nov     Dec    
        2011:   Jan     Feb     Mar     Apr     May     Jun     Jul     Aug     Sep     Oct     Nov     Dec    
        2010:   Jan     Feb     Mar     Apr     May     Jun     Jul     Aug     Sep     Oct     Nov     Dec    
        2009:   Jan     Feb     Mar     Apr     May     Jun     Jul     Aug     Sep     Oct     Nov     Dec    
        2008:   Jan     Feb     Mar     Apr     May     Jun     Jul     Aug     Sep     Oct     Nov     Dec    
        2007:   Jan     Feb     Mar     Apr     May     Jun     Jul     Aug     Sep     Oct     Nov     Dec    
        2006:   Jan     Feb     Mar     Apr     May     Jun     Jul     Aug     Sep     Oct     Nov     Dec